Live Now:

Welcome and Introduction
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
The Endocrinologist's Approach to Male Infertility
Arthi Thirumalai, MBBS
University of Washington, Seattle, WA, USA
Dr. Thirumalai is a board-certified physician at the Endocrine and Diabetes Care Center at UWMC-Roosevelt and the Atherosclerosis/Lipid Clinic at Harborview and a UW assistant professor of Medicine and Metabolism, Endocrinology and Nutrition. Dr. Thirumalai sees a wide array of patients with general endocrine problems and diabetes. She believes the only way to succeed in helping patients with these issues is to listen to their primary concerns and see how every aspect of their lives influences their medical outcomes. Dr. Thriumalai earned her M.D. at Lady Hardinge Medical Center in New Delhi, India. She is board certified in both Internal Medicine and Endocrinology/Diabetes/Metabolism and is a member of the Endocrine Society. Dr. Thirumalai’s clinical and research interests include general endocrinology including thyroid, parathyroid, adrenal, pituitary and bone disorders, diabetes, Inpatient hyperglycemia management, male reproductive physiology and male contraception.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain the different causes of male infertility
  • Identify when to do an evaluation for endocrinologic causes of male infertility
  • Interpret the diagnostic tests of male reproductive function
  • Outline a treatment algorithm for endocrine causes of male infertility.
Master Clinician: Clinical Challenges in Secondary Osteoporosis
Ann E. Kearns, MD, PhD(Moderator)
Mayo Clinic, Rochester, MN, USA
Dr. Kearns obtained her internal medicine training at the University of Chicago Hospitals, and her Endocrinology training at Massachusetts General Hospital. She joined the Mayo Clinic in Rochester, MN in 1998. She is currently the Chair of Quality and Safety in the Division of Endocrinology. Dr. Kearns has expertise in osteoporosis, calcium disorders, and metabolic bone disease. She is also involved in Quality Improvement especially in osteoporosis evaluation and management after a fracture.

Disclosures:

No relevant financial relationships.
Suzanne M. Jan de Beur, MD(Panelist)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
Benjamin Leder, MD(Panelist)
Massachusetts General Hospital, Boston, MA, USA
Dr. Leder received his medical degree from Harvard Medical School and completed his Internal Medicine Residency and Endocrine Fellowship at Massachusetts General Hospital, where he has remained ever since. His current position is Professor of Medicine at Harvard Medical School. Over the past two decades, Dr. Leder has been both an active clinician (serving as the Director of Endocrine Associates, a 16-physician practice focusing on metabolic bone disease) and clinical investigator. His NIH-funded research focuses on developing novel therapeutic approaches to the management of postmenopausal osteoporosis and other metabolic bone diseases.

Disclosures:

Advisory Board Member: Radius
Grant Recipient: Amgen
 

Learning Objectives:

  • Develop a strategy to evaluate men for secondary causes of osteoporosis
  • Utilize genetic testing in select patients to evaluate secondary causes of osteoporosis
  • Optimize nutritional factors contributing to secondary osteoporosis.
What's New in Lipid Lowering Therapies?
Michael J. Blaha, MD, MPH
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Blaha (Professor of Cardiology and Epidemiology) is the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Dr. Blaha has published over 500 scientific articles, with a focus on appropriate use of tests and new therapies in the prevention of atherosclerotic cardiovascular disease. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 20 trainees, many of which have gone on to hold prominent academic appointments. Clinically, he practices as a preventive cardiologist and in the interpretation of cardiac CT. His clinic specializes in patients with advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk.

Disclosures:

Advisory Board Member: Bayer, Kaleido, Roche
Consultant: Kowa
Grant Recipient: 89Bio, Amgen, Novo Nordisk
Research Investigator: Novartis
 

Learning Objectives:

  • Discuss the mechanism of action of new lipid-lowering pharmacotherapies
  • Review the indications for newer available lipid-lowering therapies, and discuss strategies for their use in primary and secondary prevention
  • Describe the pipeline of potential future lipid-lowering therapies.
Endocrine Debate: Testosterone Therapy in Women: Never or Sometimes?
Kathryn A. Martin, MD(Moderator)
Massachusetts General Hospital, Boston, MA, USA
Dr. Martin is a faculty member and practicing clinician in the Reproductive Endocrine Unit at Massachusetts General Hospital. She has an active teaching role, including the training and supervision of junior faculty members and endocrine fellows. Her research interests have been in the area of female reproduction, in particular, the pathophysiology and management of isolated GnRH deficiency and functional hypothalamic amenorrhea. She has written and lectured extensively on the evaluation and management of menopausal women. Dr. Martin has had a number of leadership roles in the Endocrine Society; she has been chair of several committees including the Nominating Committee and the Clinical Practice Guidelines committee, and she is currently a member of the Board of Directors. Dr. Martin is also the Senior Deputy Editor for Endocrinology and Patient Education, as well as a member of the GRADE/EBM group at UpToDate, an online clinical reference for physicians.

Disclosures:

Employee: UpToDate/WoltersKluwer
Susan R. Davis, MBBS, FRACP, PhD(Panelist)
Monash University, Melbourne, VIC, Australia
Dr. Davis is an NHMRC Senior Principal Research Fellow, Director, Monash University Women’s Health Research Program, Consultant Endocrinologist and Head, Specialist Women’s Health Clinic, Alfred Hospital Melbourne and consultant at Cabrini Medical Centre. Her research has advanced the understanding of estrogen and testosterone action, deficiency and replacement in women. She is a past president of the Australasian Menopause Society and immediate past President of the International Menopause Society. She has over 420 peer-reviewed publications and in numerous awards. In 2021 Prof Davis was appointed an Officer of the Order of Australia distinguished service to medicine, to women's health as a clinical endocrinologist and researcher, and to medical education.

Disclosures:

Advisory Board Member: Mayne Pharmaceuticals, Theramex
Consultant: Lawley Pharm, Que Oncology
Speaker: BioFemme, Besins Healthcare
Margaret E. Wierman, MD(Panelist)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Wierman is a Professor of Medicine, Integrative Physiology at the University of Colorado School of Medicine. She directs the Pituitary and Adrenal Tumor Program. Dr. Wierman is a translational physician scientist whose research interest has been in reproductive endocrinology and sex hormone action, and more recently in the molecular mechanisms of pituitary tumors and adrenal cancer. She has led many committees in the Endocrine Society and is Past Clinical Scientist Vice President. She directs the Program to Advance Gender Equity in the Department of Medicine at the University of Colorado. Dr. Wierman has a long track record in mentoring and pipeline development of academic researchers. She received the Women in Endocrinology Mentor Award and the Endocrine Society Laureate Mentor Award from the Endocrine Society. Dr. Wierman is currently the Chair of the International Society of Endocrinology

Disclosures:

Research Investigator: Corcept, Novo Nordisk
 

Learning Objectives:

  • Describe the assessment for possible testosterone therapy in post-menopausal women
  • Describe the indications for androgen therapy in women
  • Describe the data about the risk of androgen therapy in women for hypoactive sexual desire disorder.
Meet the Professor: Calcium Conundrums
Ann E. Kearns, MD, PhD(Panelist)
Mayo Clinic, Rochester, MN, USA
Dr. Kearns obtained her internal medicine training at the University of Chicago Hospitals, and her Endocrinology training at Massachusetts General Hospital. She joined the Mayo Clinic in Rochester, MN in 1998. She is currently the Chair of Quality and Safety in the Division of Endocrinology. Dr. Kearns has expertise in osteoporosis, calcium disorders, and metabolic bone disease. She is also involved in Quality Improvement especially in osteoporosis evaluation and management after a fracture.

Disclosures:

No relevant financial relationships.
Suzanne M. Jan de Beur, MD(Panelist)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
 

Learning Objectives:

  • Describe pathophysiology of basic mineral metabolism
  • Recognize the clinical presentation of disorders of hypo and hypercalcemia
  • Discuss how to optimize regimens for hypocalcemia.
Meet the Professor: When is a Lipid Panel Not Enough?
Michael J. Blaha, MD, MPH
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Blaha (Professor of Cardiology and Epidemiology) is the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Dr. Blaha has published over 500 scientific articles, with a focus on appropriate use of tests and new therapies in the prevention of atherosclerotic cardiovascular disease. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 20 trainees, many of which have gone on to hold prominent academic appointments. Clinically, he practices as a preventive cardiologist and in the interpretation of cardiac CT. His clinic specializes in patients with advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk.

Disclosures:

Advisory Board Member: Bayer, Kaleido, Roche
Consultant: Kowa
Grant Recipient: 89Bio, Amgen, Novo Nordisk
Research Investigator: Novartis
 

Learning Objectives:

  • Describe the role of other markers of CVD risk such as lipoprotein(a), apoB and hsCRP
  • Review the guidelines for measuring and using Coronary Artery Calcium scores
  • Explain the role of lipid-lowering therapies in the setting of elevated non-traditional markers of CVD risk.
T Test: What is the Best Test?
Shehzad Basaria, MD
Brigham and Women's Hospital, Boston, MA, USA
Dr. Basaria is Professor of Medicine at Harvard Medical School/Brigham and Women's Hospital, and Associate Director of the Section of Men's Health, Aging and Metabolism. His clinical and research interests are in the field of Male Reproduction. His work focuses on cardiometabolic complications of androgen deprivation therapy in men with prostate cancer and the efficacy of testosterone replacement in men with opioid-induced androgen deficiency.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the criteria for the diagnosis of the male hypogonadism
  • Identify what laboratory tests should be used to diagnose male hypogonadism
  • Explain the controversy about the value of assessment of total testosterone versus free testosterone in the diagnosis of male hypogonadism.
  • Discuss how medical conditions and medications influence serum sex steroid concentrations.
Updates in Osteoporosis Treatment
Benjamin Leder, MD
Massachusetts General Hospital, Boston, MA, USA
Dr. Leder received his medical degree from Harvard Medical School and completed his Internal Medicine Residency and Endocrine Fellowship at Massachusetts General Hospital, where he has remained ever since. His current position is Professor of Medicine at Harvard Medical School. Over the past two decades, Dr. Leder has been both an active clinician (serving as the Director of Endocrine Associates, a 16-physician practice focusing on metabolic bone disease) and clinical investigator. His NIH-funded research focuses on developing novel therapeutic approaches to the management of postmenopausal osteoporosis and other metabolic bone diseases.

Disclosures:

Advisory Board Member: Radius
Grant Recipient: Amgen
 

Learning Objectives:

  • Recognize potential causes and contributors to the current crises in osteoporosis care
  • Assess the relative efficacy and limitations of anabolic and antiresorptive osteoporosis therapies
  • Summarize the relative efficacy of various sequential and combination approaches to osteoporosis management.
What the Endocrinologist Needs to Know About the Diagnosis and Management of Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
Kenneth Cusi, MD
University of Florida, Gainesville, FL, USA
Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville, and at the Veterans Administration Medical Center at Gainesville, FL (2011-present). He completed his medical training and residency in Buenos Aires, Argentina, and fellowship in endocrinology at Baylor College of Medicine, Houston, Texas. He worked after his training at the University of San Antonio Health Science Center, Texas (1992-2011) on the role of defects in insulin secretion/insulin resistance in the development of T2DM and later focused on the underlying mechanisms and new treatments for nonalcoholic fatty liver disease (NAFLD) in T2DM. Dr. Cusi has published over 200 original articles, editorials, reviews and book chapters in the fields of diabetes, obesity and liver disease. He has contributed to several guidelines in NAFLD. His basic and clinical research programs in diabetes and fatty liver disease include funding from the NIH and from industry examining new treatments for NASH. The University of Florida awarded him in 2015 two awards, the Exemplary Teacher Award and the Clinical Research Award for Outstanding Achievement, Research Discovery, and Productivity. In 2020, he received the American Association of Clinical Endocrinologists (AACE) Jack Baskin, MD, Endocrine Teaching Award.

Disclosures:

Advisory Board Member: Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal
Research Investigator: Echosens, Inventiva, Novo Nordisk, Poxel, Zydus
 

Learning Objectives:

  • Recognize the magnitude of the problem and the mechanisms leading to steatohepatitis in patients with obesity and type 2 diabetes mellitus
  • Compare the diagnostic tools available for NAFLD and hepatic fibrosis and select the best tools for your practice
  • Evaluate current treatment modalities for steatohepatitis, both as monotherapy and in combination, and for the management of associated comorbidities (obesity, insulin resistance, dyslipidemia, CVD).
Disorders of Phosphate
Suzanne M. Jan de Beur, MD
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
 

Learning Objectives:

  • Discuss hormonal regulation phosphate homeostasis
  • Explain the differential diagnosis of hypophosphatemia and hyperphosphatemia based on clinical and biochemical characteristic
  • Describe new treatment options for some forms of FGF23 mediated hypophosphatemia.
Master Clinician: Alopecia in Women: The Endocrinologist's Approach
Margaret E. Wierman, MD(Moderator)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Wierman is a Professor of Medicine, Integrative Physiology at the University of Colorado School of Medicine. She directs the Pituitary and Adrenal Tumor Program. Dr. Wierman is a translational physician scientist whose research interest has been in reproductive endocrinology and sex hormone action, and more recently in the molecular mechanisms of pituitary tumors and adrenal cancer. She has led many committees in the Endocrine Society and is Past Clinical Scientist Vice President. She directs the Program to Advance Gender Equity in the Department of Medicine at the University of Colorado. Dr. Wierman has a long track record in mentoring and pipeline development of academic researchers. She received the Women in Endocrinology Mentor Award and the Endocrine Society Laureate Mentor Award from the Endocrine Society. Dr. Wierman is currently the Chair of the International Society of Endocrinology

Disclosures:

Research Investigator: Corcept, Novo Nordisk
Andrea Kalus, MD(Panelist)
University of Washington, Seattle, WA, USA
Dr. Kalus, co-directs the Rheumatology-Dermatology Clinic at the UW Roosevelt Clinic. Her clinical practice focuses on autoimmune diseases, complex medical dermatology and phototherapy. Dr. Kalus earned her M.D. at the University of Washington. She completed residency training in both internal medicine and dermatology. Dr. Kalus partners with multidisciplinary research teams to study lupus, dermatomyositis and skin manifestations of systemic disease.

Disclosures:

Grant Recipient: Janssen, Lilly
Kathryn A. Martin, MD(Panelist)
Massachusetts General Hospital, Boston, MA, USA
Dr. Martin is a faculty member and practicing clinician in the Reproductive Endocrine Unit at Massachusetts General Hospital. She has an active teaching role, including the training and supervision of junior faculty members and endocrine fellows. Her research interests have been in the area of female reproduction, in particular, the pathophysiology and management of isolated GnRH deficiency and functional hypothalamic amenorrhea. She has written and lectured extensively on the evaluation and management of menopausal women. Dr. Martin has had a number of leadership roles in the Endocrine Society; she has been chair of several committees including the Nominating Committee and the Clinical Practice Guidelines committee, and she is currently a member of the Board of Directors. Dr. Martin is also the Senior Deputy Editor for Endocrinology and Patient Education, as well as a member of the GRADE/EBM group at UpToDate, an online clinical reference for physicians.

Disclosures:

Employee: UpToDate/WoltersKluwer
 

Learning Objectives:

  • Describe the pathophysiology of common causes of alopecia in women
  • Diagnose female pattern hair loss.
  • Recognize the clinical features and diagnostic approach to scarring and non-scarring hair loss
  • Identify the diagnostic evaluation for endocrinopathies in women who have alopecia.
  • Discuss the treatment options for common causes of alopecia in women.
Meet the Professor: Overcoming Barriers to Obesity Therapy, a Case-Based Approach
Ania M. Jastreboff, MD, PhD
Yale School of Medicine, New Haven, CT, USA
Dr. Jastreboff is an Associate Professor of Internal Medicine & Pediatrics (Endocrinology & Pediatric Endocrinology) at Yale University School of Medicine, Director of Weight Management and Obesity Prevention at the Yale Stress Center, and co-Director of the Yale Center for Weight Management. After completing a Med/Peds Residency, Dr. Jastreboff completed a dual fellowship in both Adult Endocrinology and Pediatric Endocrinology during which she also completed a PhD in the neurobiology of obesity, becoming board certified in Obesity Medicine, Adult Endocrinology, and Pediatric Endocrinology. Dr. Jastreboff is a clinically active physician-scientist nationally and internationally recognized for helping to develop the 2016 Clinical Practice Guidelines for The Comprehensive Care of Patients with Obesity (AACE/ACE), educating the next generation of Obesity Medicine physicians by teaching annually at the Harvard Blackburn Treating Obesity course, the Columbia/Cornell Obesity course, selected international courses, and conducting cutting-edge clinical translational obesity research. Her research includes both large, multi-center clinical outcomes trials using anti-obesity medication as well as neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and the mechanisms of anti-obesity medications. Dr. Jastreboff's research is supported by NIH/NIDDK (K23, R01s), American Diabetes Association (ADA), and industry funded multi-center clinical trials. Nationally, she serves as the vice-Chair of the Clinical Care Committee of The Obesity Society (TOS) and has been selected to serve as a Director on the American Board of Obesity Medicine (ABOM). Clinically, Dr. Jastreboff specializes in sophisticated use of anti-obesity medication combinations to help patients reach their weight and health goals.

Disclosures:

Consultant: Boehringer Ingelheim, Eli Lilly, Novo Nordisk
Grant Recipient: American Diabetes Association, NIH/NIDDK
Site-PI for Multi-Center Trial: Eli Lilly, Novo Nordisk
 

Learning Objectives:

  • Identify and overcome barriers to treating obesity
  • Become familiar with available anti-obesity medications and key concepts in their use for treating patients with obesity
  • Understand the importance of comprehensive care for individuals with obesity.
Ancillary Symposium: Challenges in Diagnosing and Managing Patients with Fibrodysplasia Ossificans Progressiva
Welcome and Introduction
Kelly L. Wentworth, MD
University of California, San Francisco, San Francisco, CA, USA
Dr. Wentworth is an Assistant Professor in the Department of Medicine, Division of Endocrinology at Zuckerberg San Francisco General Hospital, University of California, San Francisco. She has a clinical and research interest in metabolic bone disorders, with a specific focus on fibrous dysplasia/McCune-Albright Syndrome and fibrodysplasia ossificans progressiva (FOP).  She is currently funded by an NIH/NIDCR K08 career development grant.

Disclosures:

Research Investigator: Ipsen pharmaceuticals
Clinical Presentation and Treatment Options for Patients with FOP
Mona Al Mukaddam, MD, MS(Panelist)
Penn Medicine University City, Philadelphia, PA, USA
Dr. Al Mukaddam is an adult endocrinologist in the Division of Endocrinology, Diabetes and Metabolism at the Pennsylvania and Director of the Penn Bone Center. Dr. Al Mukaddam received her Bachelor of Science and Medical Degrees from American University in Beirut, Lebanon. She completed her internship and residency in internal medicine at the University of Iowa, a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Penn, and received a Master of Science Degree in translational medicine and therapeutics at the University of Pennsylvania. Dr. Al Mukaddam is board certified in endocrinology, diabetes and metabolism. She is the principal investigator on ongoing clinical trials in FOP at the Center for Research in FOP & Related Disorders at Penn and is a founding member of the International Clinical Council on FOP (ICC).

Disclosures:

Research Investigator: Clementia/Ipsen Pharmaceuticals, Regeneron
Elisabeth M.W. Eekhoff, MD, PhD(Panelist)
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Basic and Translational Science Advancements in FOP
Benjamin Levi, MD
UT Southwestern Medical Center, Boston, MA, USA
Dr. Levi holds the Dr. Lee Hudson-Robert R. Penn Chair in Surgery and Plastic and Reconstructive Surgery and serves as Chief of the Division of Burn, Trauma, Acute and Critical Care Surgery. He specializes in acute and reconstructive burn surgery and scar reconstructive surgery. Certified by the American Board of Plastic Surgery and the American Board of Surgery, Dr. Levi joined the UT Southwestern faculty in 2020. Previously, he was Director of the Burn/Wound and Regenerative Medicine Laboratory and Associate Director of Burn Surgery Service at the University of Michigan. Dr. Levi’s research interests, which are funded by the National Institutes of Health, the American College of Surgeons, and the Department of Defense, include stem cell biology, heterotopic ossification, muscle fibrosis, tissue regeneration, wound healing and repair, and burn reconstruction outcomes.

Disclosures:

No relevant financial relationships.
Future Management Options for Patients with FOP
Elisabeth M.W. Eekhoff, MD, PhD
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Post-test, Panel Discussion, and Q&A
Kelly L. Wentworth, MD(Moderator)
University of California, San Francisco, San Francisco, CA, USA
Dr. Wentworth is an Assistant Professor in the Department of Medicine, Division of Endocrinology at Zuckerberg San Francisco General Hospital, University of California, San Francisco. She has a clinical and research interest in metabolic bone disorders, with a specific focus on fibrous dysplasia/McCune-Albright Syndrome and fibrodysplasia ossificans progressiva (FOP).  She is currently funded by an NIH/NIDCR K08 career development grant.

Disclosures:

Research Investigator: Ipsen pharmaceuticals
Mona Al Mukaddam, MD, MS(Panelist)
Penn Medicine University City, Philadelphia, PA, USA
Dr. Al Mukaddam is an adult endocrinologist in the Division of Endocrinology, Diabetes and Metabolism at the Pennsylvania and Director of the Penn Bone Center. Dr. Al Mukaddam received her Bachelor of Science and Medical Degrees from American University in Beirut, Lebanon. She completed her internship and residency in internal medicine at the University of Iowa, a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Penn, and received a Master of Science Degree in translational medicine and therapeutics at the University of Pennsylvania. Dr. Al Mukaddam is board certified in endocrinology, diabetes and metabolism. She is the principal investigator on ongoing clinical trials in FOP at the Center for Research in FOP & Related Disorders at Penn and is a founding member of the International Clinical Council on FOP (ICC).

Disclosures:

Research Investigator: Clementia/Ipsen Pharmaceuticals, Regeneron
Elisabeth M.W. Eekhoff, MD, PhD(Panelist)
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Benjamin Levi, MD(Panelist)
UT Southwestern Medical Center, Boston, MA, USA
Dr. Levi holds the Dr. Lee Hudson-Robert R. Penn Chair in Surgery and Plastic and Reconstructive Surgery and serves as Chief of the Division of Burn, Trauma, Acute and Critical Care Surgery. He specializes in acute and reconstructive burn surgery and scar reconstructive surgery. Certified by the American Board of Plastic Surgery and the American Board of Surgery, Dr. Levi joined the UT Southwestern faculty in 2020. Previously, he was Director of the Burn/Wound and Regenerative Medicine Laboratory and Associate Director of Burn Surgery Service at the University of Michigan. Dr. Levi’s research interests, which are funded by the National Institutes of Health, the American College of Surgeons, and the Department of Defense, include stem cell biology, heterotopic ossification, muscle fibrosis, tissue regeneration, wound healing and repair, and burn reconstruction outcomes.

Disclosures:

No relevant financial relationships.
supported by:
This program is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.
 

Learning Objectives:

  • Analyze clinical presentations of FOP in individuals
  • Review the importance of early diagnosis and management of FOP
  • Describe the best practices in the diagnosis and management of patients with FOP
Welcome and Introduction
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
Automated Insulin Delivery in the Management of T1DM
Anne L. Peters, MD
University of Southern California, Los Angeles, CA, USA
Dr. Peters is a Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes programs at Cedars-Sinai and UCLA. Her research has focused on testing new approaches for diagnosing and treating diabetes and developing systems of care to improve outcomes in diabetic populations. She has published over 200 articles, reviews, and abstracts and three books on diabetes. She has been an investigator on over 40 research studies and has spoken at over 400 programs throughout the US as well as internationally. She has served on many committees for the ADA and other organizations. Currently she is the chair of the Endocrine Society Committee on Diabetes Devices and is on the EASD/ADA Technology Safety Committee. Additionally she is a member of the JDRF Panel on Management of Exercise in Type 1 Diabetes. She is a member of the ABIM Endocrinology Subspecialty Board. She consults for many entities, including the FDA, Optum Rx and CVS/Caremark to help guide the development and use of treatments for diabetes.

Disclosures:

Advisory Board Member: Eli Lilly, Novo Nordisk, Zealand
Research Investigator: Abbot Diabetes Care, Dexcom, Insulet
Stock Options: Omada Health, Teladoc
 

Learning Objectives:

  • Review the strengths of hybrid closed loop technology
  • Summarize the weaknesses of hybrid closed loop technology
  • Identify patients who would benefit most from closed-loop technologies and those for whom it may not be appropriate.
Master Clinician: CKD and Diabetes: Management of Diabetes in Patients with Progressive CKD
Rita R. Kalyani, MD, MHS(Moderator)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Kalyani is an Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at Johns Hopkins University School of Medicine. She graduated with an undergraduate degree from Harvard College and completed her medical degree, residency, and fellowship at Johns Hopkins. Dr. Kalyani is an active clinician and sees patients regularly in the Johns Hopkins Comprehensive Diabetes Center. She directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program. A recipient of NIH grant funding, Dr. Kalyani's research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases. She has served on the editorial boards of several diabetes research journals and has authored more than 125 peer-reviewed publications. Dr. Kalyani is a past Chair of the American Diabetes Association’s Professional Practice Committee which is responsible for the annual clinical guidelines statement, “ADA Standards of Medical Care in Diabetes”. She is the Editor-in-Chief of the Johns Hopkins Patient Guide to Diabetes website. Dr. Kalyani currently serves on the Clinical Guidelines Committee for the Endocrine Society.

Disclosures:

No relevant financial relationships.
Silvio E. Inzucchi, MD(Panelist)
Yale School of Medicine, New Haven, CT, USA
Dr. Inzucchi is a Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center. He is well known as an author and lecturer in diabetes management for more than two decades. He served as co-chair of the ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes and has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.

Disclosures:

Advisory Board Member: Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Lexicon, Merck, Novo Nordisk, VTV Therapeutics
Consultant: Abbott, Esperion, Merck, vTv Therapeutics
Speaker: AstraZeneca, Boehringer Ingelheim
Clinical Trial Publications Committee Member: Boehringer Ingelheim
Clinical Trial Executive Committee Member: AstraZeneca
Clinical Trial Steering Committee Member: Novo Nordisk
Robert C. Stanton, MD(Panelist)
Joslin Diabetes Center, Boston, MA, USA
Dr. Stanton is Chief of the Kidney and Hypertension Section at the Joslin Diabetes Center, a Principal Investigator (Section on Vascular Cell Biology), and an Associate Professor of Medicine at Harvard Medical School. Dr. Stanton has given many invited lectures throughout the world and written many original articles and reviews on clinical and basic science aspects of diabetic kidney disease. Dr. Stanton’s research is focused on the essential enzyme, glucose 6-phosphate dehydrogenase (G6PD). His lab has discovered that this enzyme (and associated pathway) is essential for cell survival and dysregulation of G6PD plays an important role in the pathogenesis of many diseases. He has received honorary professorships from other universities and a major lifetime-achievement teaching award for Sustained Excellence in Teaching from Harvard Medical School.

Disclosures:

Advisory Board Member: Bayer Pharmaceuticals
 

Learning Objectives:

  • Discuss the renoprotection of new antihyperglycemic agents
  • Describe safe use of antihyperglycemic medications in patients with kidney disease
  • Identify clinical trials demonstrating that specific antihyperglycemic drugs delay the progression of kidney disease.
Meet the Professor: Tips for Clinicians for Genetic Evaluations of Adrenal Disorders
Lauren Fishbein, MD, PhD
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Fishbein is an Associate Professor at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes. She earned an MD, PhD degree from the University of Florida, and completed Internal Medicine Residency at Harvard’s Beth Israel Deaconess Medical Center and Endocrinology Fellowship at the University of Pennsylvania. Her research and clinical interests are in neuroendocrine tumor genetics. Dr. Fishbein has a strong interest in personalized medicine including understanding the impact of germline predisposition genetics, as well as understanding neuroendocrine tumor development and metastatic disease. Dr. Fishbein is a member of the Endocrine Society’s Annual Meeting Steering Committee and previously served as co-chair of the Trainee and Career Development Core Committee.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify when to refer a patient with an adrenal tumor for clinical genetic testing
  • List genetic predisposition syndromes associated with adrenal tumor.
  • Describe how to screen patients with hereditary predisposition for pheochromocytoma/paraganglioma.
Health Disparities in Diabetes
Rocio I. Pereira, MD
Denver Health, Denver, CO, USA
Dr. Pereira is the Chief of Endocrinology at Denver Health, Associate Professor of Medicine at the University of Colorado, Division of Endocrinology, Metabolism, and Diabetes, and the Founder and Director of the Vuela for Health lifestyle intervention program for Latino immigrants. The primary focus of Dr. Pereira’s work is addressing health disparities in diabetes and obesity. Dr. Pereira has been a member of the Endocrine Society since 2001. She has served as Chair of the Minority Affairs Committee/Committee on Diversity and Inclusion (CODI), and contributed to a number of other Society efforts. Dr. Pereira is currently a member of the Board of Directors, Board representative to CODI, and the Program Director for the upcoming EXCEL- Excellence in Clinical Endocrinology and Leadership program.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Summarize the nature and extent of disparities in diabetes affecting national and global racial and ethnic minority communities
  • Recognize systemic racism as the fundamental underlying cause of health disparities
  • Apply knowledge of health equity best practices to identify actions to address health disparities.
Meet the Professor: Management of Adrenal Tumors in Pregnancy
William F. Young Jr., MD, MSc
Mayo Clinic, Rochester, MN, USA
Dr. Young is the Tyson Family Endocrinology Clinical Professor and Professor of Medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minnesota, USA. He is the recipient of multiple education awards and is a past president of the Endocrine Society and past chair of the Division of Endocrinology at Mayo Clinic. Dr. Young’s clinical research focuses on primary aldosteronism and pheochromocytoma. He has published more than 300 articles on endocrine hypertension and adrenal and pituitary disorders. He has delivered more than 650 presentations at national and international meetings and he has been an invited visiting professor for more than 150 medical institutions.

Disclosures:

Adrenal Safety Monitor for Progesterone Receptor Modulator Trial: Bayer
 

Learning Objectives:

  • Discuss treatment options for the woman with a catecholamine-secreting tumor diagnosed during pregnancy
  • Review the potential effects of pregnancy on underlying primary aldosteronism and impact on treatment decisions
  • Determine the most likely cause for Cushing syndrome during pregnancy to direct optimal management.
Meet the Professor: Pancreatogenic Diabetes
Rita R. Kalyani, MD, MHS
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Kalyani is an Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at Johns Hopkins University School of Medicine. She graduated with an undergraduate degree from Harvard College and completed her medical degree, residency, and fellowship at Johns Hopkins. Dr. Kalyani is an active clinician and sees patients regularly in the Johns Hopkins Comprehensive Diabetes Center. She directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program. A recipient of NIH grant funding, Dr. Kalyani's research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases. She has served on the editorial boards of several diabetes research journals and has authored more than 125 peer-reviewed publications. Dr. Kalyani is a past Chair of the American Diabetes Association’s Professional Practice Committee which is responsible for the annual clinical guidelines statement, “ADA Standards of Medical Care in Diabetes”. She is the Editor-in-Chief of the Johns Hopkins Patient Guide to Diabetes website. Dr. Kalyani currently serves on the Clinical Guidelines Committee for the Endocrine Society.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss the relationship of pancreatic disease to the development of diabetes
  • Describe the different etiologies for pancreatogenic diabetes
  • Outline unique considerations in diabetes management in pancreatogenic diabetes.
Important and Practice-Changing Publications in Diabetes, 2021
Silvio E. Inzucchi, MD
Yale School of Medicine, New Haven, CT, USA
Dr. Inzucchi is a Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center. He is well known as an author and lecturer in diabetes management for more than two decades. He served as co-chair of the ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes and has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.

Disclosures:

Advisory Board Member: Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Lexicon, Merck, Novo Nordisk, VTV Therapeutics
Consultant: Abbott, Esperion, Merck, vTv Therapeutics
Speaker: AstraZeneca, Boehringer Ingelheim
Clinical Trial Publications Committee Member: Boehringer Ingelheim
Clinical Trial Executive Committee Member: AstraZeneca
Clinical Trial Steering Committee Member: Novo Nordisk
 

Learning Objectives:

  • Summarize key findings from recent practice-changing publications in diabetes
  • Explain the context of recent important publications in diabetes
  • Outline potential implications of recent key publications in diabetes.
Master Clinician: Chromaffin Tumors Perspectives
Lauren Fishbein, MD, PhD(Moderator)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Fishbein is an Associate Professor at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes. She earned an MD, PhD degree from the University of Florida, and completed Internal Medicine Residency at Harvard’s Beth Israel Deaconess Medical Center and Endocrinology Fellowship at the University of Pennsylvania. Her research and clinical interests are in neuroendocrine tumor genetics. Dr. Fishbein has a strong interest in personalized medicine including understanding the impact of germline predisposition genetics, as well as understanding neuroendocrine tumor development and metastatic disease. Dr. Fishbein is a member of the Endocrine Society’s Annual Meeting Steering Committee and previously served as co-chair of the Trainee and Career Development Core Committee.

Disclosures:

No relevant financial relationships.
Anand Vaidya, MD, MMSc(Panelist)
Brigham and Women's Hospital, Boston, MA, USA
Dr. Vaidya is currently the Director of the Center for Adrenal Disorders at Brigham and Women’s Hospital and an Associate Professor at Harvard Medical School. He oversees the multi-disciplinary clinical care of patients with adrenal diseases and runs a translational research program. His research has helped characterize and redefine the severity spectrum of primary aldosteronism, the optimal approaches to treating primary aldosteronism, the genetics of pheochromocytoma-paraganglioma syndromes, and the systemic consequences of adrenal tumors and hypercortisolism. Dr. Vaidya is a dedicated educator; he is the director of the pre-clerkship endocrinology curriculum at HMS, he directs the interactive medical case series for the New England Journal of Medicine, and he regularly teaches clinical audiences about updates in adrenal diseases.

Disclosures:

Advisory Board Member: Mineralys
Consultant: Corcept, HRA Pharma
William F. Young Jr., MD, MSc(Panelist)
Mayo Clinic, Rochester, MN, USA
Dr. Young is the Tyson Family Endocrinology Clinical Professor and Professor of Medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minnesota, USA. He is the recipient of multiple education awards and is a past president of the Endocrine Society and past chair of the Division of Endocrinology at Mayo Clinic. Dr. Young’s clinical research focuses on primary aldosteronism and pheochromocytoma. He has published more than 300 articles on endocrine hypertension and adrenal and pituitary disorders. He has delivered more than 650 presentations at national and international meetings and he has been an invited visiting professor for more than 150 medical institutions.

Disclosures:

Adrenal Safety Monitor for Progesterone Receptor Modulator Trial: Bayer
 

Learning Objectives:

  • Describe how to do work up a patient with elevated catecholamines/metanephrines
  • Describe pitfalls of imaging and biochemical studies in the diagnosis of pheochromocytoma/paraganglioma
  • Select which imaging study is best for identifying pheochromocytoma/paraganglioma.
Utility of Adrenal Androgens in Clinical Practice
Adina F. Turcu, MD, MS
University of Michigan, Ann Arbor, MI, USA
Dr. Turcu is an Assistant Professor of Internal Medicine at University of Michigan, Ann Arbor. Dr. Turcu completed her Endocrinology fellowship at Mayo Clinic, Rochester, MN, and subsequently pursued a postdoctoral fellowship with focus on adrenal pathophysiology and steroid biology at the University of Michigan. Dr. Turcu’s research focuses on primary aldosteronism, congenital adrenal hyperplasia, Cushing syndrome, and adrenal androgenesis across ages. She has expertise in mass spectrometry and has a particular interest in identifying novel biomarkers with clinical relevance in adrenal disorders. Dr. Turcu’s research is currently supported by the NIH and by a Doris Duke Foundation Clinical Scientist Development Award. Dr. Turcu is the recipient of numerous prestigious awards, such as the Mayo Clinic Randall G. Sprague Award for outstanding clinical, investigative, and academic achievement in Endocrinology; the Women in Endocrinology Young Investigator Award; the Endocrine Society Early Investigators Award; and the ASCI's 2020 Young Physician-Scientist Awards.

Disclosures:

Advisory Board Member: CinCor
Consultant: Chiasma, Crinetics, PhaseBio, Poxel
 

Learning Objectives:

  • Discuss physiological sources of androgens, with emphasis on adrenal androgens
  • Identify the clinical utility of adrenal androgens in the diagnosis and management of disorders of androgens excess (Congenital adrenal hyperplasia, PCOS, Premature adrenarche)
  • Identify the clinical utility of adrenal androgens in assessing the hypothalamic-pituitary-adrenal axis (adrenal insufficiency and autonomous hypercortisolism).
Meet the Professor: Facing the Challenges of Severe Insulin Resistance
Anastassia Amaro, MD
University of Pennsylvania, Philadelphia, PA, USA
Dr. Amaro is an Associate Professor of Clinical Medicine in the Division of Endocrinology and Metabolism at the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Amaro, a graduate from Sechenov Moscow Medical Academy in Moscow, Russia, completed her residency in Internal Medicine at Lutheran General Hospital in Chicago, Illinois. Her fellowship training in Endocrinology and Metabolism was at Washington University and at the Barnes-Jewish Hospital in St. Louis, Missouri. Double-boarded in Endocrinology and Obesity Medicine, Dr. Amaro established Penn Metabolic Medicine (PMM) center and has been serving as the Medical Director of PMM since 2015. Penn Metabolic Medicine is a unique translational clinic dedicated to clinical care and research in subjects with obesity and abnormalities of carbohydrate metabolism. Dr. Amaro serves as an investigator on several clinical trials in obesity and diabetes.

Disclosures:

Advisory Board Member: Novo Nordisk
Research Investigator: Fractyl Laboratories, Inc.
 

Learning Objectives:

  • Summarize current medical knowledge of mechanisms of insulin resistance at various tissue levels
  • Discuss the therapeutic challenges of severe insulin resistance
  • Identify clinical strategies for maintaining glycemic control in severely insulin resistant patients.
Prevention and Management of Hypoglycemia
Kasia J. Lipska, MD, MHS
Yale School of Medicine, New Haven, CT, USA
Dr. Lipska is an Associate Professor of Medicine (Endocrinology) at the Yale School of Medicine and a Clinical Investigator at the Yale-New Haven Hospital Center for Outcomes Research and Evaluation (CORE). She received her medical degree from Harvard Medical School, completed internal medicine residency at the Brigham and Women’s Hospital, and her endocrine training at the Yale School of Medicine, where she also received a Masters degree in Health Science through the Robert Wood Johnson Clinical Scholars Program. Currently, she cares for patients at the Yale Diabetes Center, directs an NIH-funded research program focused on improving the safety and effectiveness of treatment of type 2 diabetes mellitus, and mentors students, trainees, and early stage faculty in diabetes outcomes research.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify risk factors for hypoglycemia
  • Describe strategies to reduce the risk of hypoglycemia
  • Outline the available treatments for hypoglycemia including newer formulations of glucagon.
Primary Aldosteronism: Once a Zebra, Now a Horse
Anand Vaidya, MD, MMSc
Brigham and Women's Hospital, Boston, MA, USA
Dr. Vaidya is currently the Director of the Center for Adrenal Disorders at Brigham and Women’s Hospital and an Associate Professor at Harvard Medical School. He oversees the multi-disciplinary clinical care of patients with adrenal diseases and runs a translational research program. His research has helped characterize and redefine the severity spectrum of primary aldosteronism, the optimal approaches to treating primary aldosteronism, the genetics of pheochromocytoma-paraganglioma syndromes, and the systemic consequences of adrenal tumors and hypercortisolism. Dr. Vaidya is a dedicated educator; he is the director of the pre-clerkship endocrinology curriculum at HMS, he directs the interactive medical case series for the New England Journal of Medicine, and he regularly teaches clinical audiences about updates in adrenal diseases.

Disclosures:

Advisory Board Member: Mineralys
Consultant: Corcept, HRA Pharma
 

Learning Objectives:

  • Identify primary aldosteronism as a highly prevalent and unrecognized syndrome that manifests across a continuum of severity
  • Describe how to recalibrate diagnostic interpretations to maximize diagnosis and treatment
  • Recognize how primary aldosteronism syndrome contributes to the pathogenesis of a large proportion of “idiopathic” hypertension and cardiovascular disease.
Ancillary Symposium: New Heights in Growth Hormone Deficiency: Advancements in Adult Patient Care
Welcome and Introduction
John D. Carmichael, MD
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Unique Diagnostic Challenges in Adult GHD
John D. Carmichael, MD
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Current, New, and Emerging GHD Therapeutic Options
Nicholas A. Tritos, MD, DSc
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Dr. Tritos is a staff neuroendocrinologist in the Neuroendocrine and Pituitary Tumor Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital (MGH) in Boston. He completed medical studies at The University of Athens (MD, DSc) and at Harvard Medical School (MMSc) where he now serves as Associate Professor of Medicine. Dr. Tritos completed his postgraduate medical training at Beth Israel Medical Center in Boston and received board certifications from the American Board of Internal Medicine in Endocrinology, Diabetes and Metabolism and Internal Medicine. Dr. Tritos’ main clinical and research interests include pituitary disease, growth hormone deficiency in adults and regulation of energy homeostasis. He mainly conducts clinical research focusing on pituitary tumors and growth hormone deficiency in adults. Dr. Tritos has served on the Curriculum Committee at Tufts University School of Medicine, currently serves as Chair of the Endocrine Fellowship Curriculum Committee, is a member of the Institutional Review Board and the Clinical Competency Committee at MGH, a subspecialty core educator for endocrinology, and the Director of the Endocrine and Neuroendocrine Electives for MGH medical residents. He has also served on several national and international Committees in professional organizations, including the Endocrine Society, the American Association of Clinical Endocrinologists and the Pituitary Society.

Disclosures:

No relevant financial relationships.
Post-test, Panel Discussion, and Q&A
John D. Carmichael, MD(Co-Panelist)
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Nicholas A. Tritos, MD, DSc(Co-Panelist)
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Dr. Tritos is a staff neuroendocrinologist in the Neuroendocrine and Pituitary Tumor Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital (MGH) in Boston. He completed medical studies at The University of Athens (MD, DSc) and at Harvard Medical School (MMSc) where he now serves as Associate Professor of Medicine. Dr. Tritos completed his postgraduate medical training at Beth Israel Medical Center in Boston and received board certifications from the American Board of Internal Medicine in Endocrinology, Diabetes and Metabolism and Internal Medicine. Dr. Tritos’ main clinical and research interests include pituitary disease, growth hormone deficiency in adults and regulation of energy homeostasis. He mainly conducts clinical research focusing on pituitary tumors and growth hormone deficiency in adults. Dr. Tritos has served on the Curriculum Committee at Tufts University School of Medicine, currently serves as Chair of the Endocrine Fellowship Curriculum Committee, is a member of the Institutional Review Board and the Clinical Competency Committee at MGH, a subspecialty core educator for endocrinology, and the Director of the Endocrine and Neuroendocrine Electives for MGH medical residents. He has also served on several national and international Committees in professional organizations, including the Endocrine Society, the American Association of Clinical Endocrinologists and the Pituitary Society.

Disclosures:

No relevant financial relationships.
supported by:
This program is supported by an educational grant from Novo Nordisk, Inc., and Sandoz, Inc.
 

Learning Objectives:

  • Apply current guidelines, testing, and criteria in the individualized management of adult GHD
  • Recognize and effectively address barriers towards treatment adherence in pediatric patients transitioning to adult care
  • Analyze currently approved therapeutic regimens as well as emerging pharmaceuticals and delivery devices for adult patients with GHD.
Legislation & Regulations Affecting Endocrinologists: What You Need to Know About Medicare Physician Payment, Telehealth Expansion, and Drug Pricing
Joshua J. Joseph, MD, MPH, FAHA(Panelist)
The Ohio State University Wexner Medical Division of Endocrinology, Diabetes and Metabolism, Columbus, OH, USA
Dr. Joshua Joseph is the Assistant Professor, Endocrinology, Diabetes and Metabolism, at The Ohio State University Wexner Medical Center. Dr. Joseph is an alumnus of Boston University School of Medicine, during which he spent two years at the National Institutes of Health in the Medical Research Scholars Program. In his diabetes and cardiovascular disease clinic, Dr. Joseph focuses on lifestyle behaviors and medical therapeutics through a team-based, patient-centered approach to living with diabetes that is tailored to provide patients with the necessary tools to successfully manage their diabetes.

Disclosures:

Associate Editor, Ethnicity & Health, American Heart Association Science Advisory and Coordinating Committee, Buckeye Health Plan Board Member
Erika Miller, JD(Panelist)
CRD Associates, Washington, DC, USA
Erika Miller is a consultant to the Endocrine Society where she brings her broad experience in government relations representing a range non- profit organizations ranging from medical specialty societies, coalitions, and patient advocacy organizations, including a number engaged on women’s health issues. Erika has expertise in the intricacies of Medicare policy and provides guidance on health policy, health care payment and quality.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Analyze new legislation and regulations concerning Medicare payment, telehealth expansion, and drug pricing
  • Understand the impact of the Medicare physician payment rule on their practice
  • Identify opportunities to share information with their patients about telehealth expansion and access to lower cost medications
  • Influence these policies and share their concerns by joining Endocrine Society campaigns
Thyroid Eye Disease: Early Diagnosis, Referral, and Treatment With TEPEZZA® (teprotumumab-trbw)
Raymond S. Douglas, MD, PhD
Cedars-Sinai Medical Center, Los Angeles, CA, USA

Disclosures:

Consultant for Horizon Therapeutics and Immunovant.
sponsored by:
Horizon Therapeutics
 

Learning Objectives:

  • Describe the pathophysiology of Thyroid Eye Disease (TED)
  • Review the clinical signs and symptoms of TED to ensure an early diagnosis and referral to a TED specialist
  • Emphasize the importance of multidisciplinary TED management
  • Provide an overview of TEPEZZA efficacy, safety, and mechanism of action for the treatment of TED
Welcome and Introduction
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
Master Clinician: Management of Aggressive Pituitary Tumors: When to Consider Alternative Nonsurgical Treatments
Lisa B. Nachtigall, MD(Moderator)
Massachusetts General Hospital, Boston, MA, USA
Dr. Nachtigall is an Associate Professor of Medicine at Harvard Medical School, clinical director of the Neuroendocrine and Pituitary Tumor Clinical Center, director of International Programs for the Endocrine Division at Massachusetts General Hospital, and clerkship director for Neuroendocrine at Harvard Medical School. Dr. Nachtigall earned her medical degree from New York University (NYU) School of Medicine, completed her internship and residency in internal medicine at Bellevue Hospital Center/NYU school of Medicine, and a clinical fellowship in endocrinology and metabolism at Massachusetts General Hospital/Harvard Medical School. She has been published in many high impact journals, serves on the editorial board of Pituitary and has presented at many national and international medical conferences in the field of pituitary disorders.

Disclosures:

Advisory Board Member: Recordati, Strongbridge
Research Investigator: Chiasma
Anthony P. Heaney, MD, PhD(Panelist)
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
Edward R. Laws, MD(Panelist)
Brigham and Women's Hospital, Boston, MA, USA
Dr. Laws received his bachelor's degree from Princeton University with honors in Economics and Sociology in the Special Program in American Civilization, and then attended the Johns Hopkins University School of Medicine in Baltimore, Maryland. He did his surgical internship and neurosurgical residency at Johns Hopkins. After completing his residency, he joined the faculty at the Johns Hopkins Medical School. In 1972, he moved to the Mayo Clinic in Rochester, Minnesota where he became Professor of Neurosurgery and developed major interests in Pituitary and Brain tumor treatment and research.  In 1987, he became Professor and Chairman of the Department of Neurosurgery at the George Washington University in Washington, DC, and in 1992 joined the faculty of the University of Virginia as Professor of Neurosurgery and Professor of Medicine, developing a Multidisciplinary Pituitary Center there. Subsequently, he was Professor of Neurosurgery at Stanford University. In 2008, he established the Pituitary/Neuroendocrine Center at Brigham and Women's Hospital, where he currently is Professor of Neurosurgery at Harvard Medical School. During his surgical career he has operated upon more than 8,000 brain tumors, of which over 6,000 have been pituitary lesions. Dr. Laws has served as President of the World Federation of Neurosurgical Societies, President of the Congress of Neurological Surgeons, Editor of Neurosurgery, President of the American Association of Neurological Surgeons, and President of the Pituitary Society. He has been the fifth neurosurgeon to become President of the American College of Surgeons and was elected to membership in the National Academy of Medicine. He remains actively involved in Brain and Pituitary tumor research and surgery.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain what the current concept of an "aggressive" pituitary tumor is
  • Discuss the role of a multidisciplinary approach to management of this entity
  • Identify up-to-date therapeutic options for these tumors.
Meet the Professor: Thyroid on the Internet: Myths and Misperceptions
Anne R. Cappola, MD, ScM
University of Pennsylvania, Philadelphia, PA, USA
Dr. Cappola is a Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism, Director of Clinical Research in the Department of Medicine, and Director of the CTSA-funded Center for Human Phenomic Science at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cappola directs an NIH-funded research program on the hormonal alterations that occur with aging and the clinical impact of these changes, with a focus on the clinical impact of subclinical thyroid dysfunction in older individuals. Dr. Cappola is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the Interurban Clinical Club and an Associate Editor for JAMA.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the types of thyroid information that patients find on the internet
  • Review scientific evidence that supports or refutes internet claims as well as areas for which there is no scientific evidence
  • Select a framework for discussing thyroid information found on the internet with patients.
The Year in Thyroid
Anthony Hollenberg, MD
Weill Cornell Medicine, New York, NY, USA
Dr. Hollenberg is the Sanford I. Weill Chair of Medicine in the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and the Physician-in-Chief at New York-Presbyterian Hospital. Dr. Hollenberg received his M.D. from the University of Calgary in Canada in 1986. He completed his Internal Medicine residency in 1989 and was Chief Resident in Medicine from 1990 to 1991 at the Beth Israel Hospital. Dr. Hollenberg then completed a fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital in 1993 and was recruited back to Beth Israel to start his laboratory. From 2011 until his recruitment to Weill Cornell Medicine and New York-Presbyterian Hospital, Dr. Hollenberg was Chief of the Division of Endocrinology, Diabetes and Metabolism, at Beth Israel Deaconess Medical Center and Director of Clinical and Translational Research Training Programs at Harvard Catalyst and Harvard Medical School where he was also a Professor of Medicine. Dr. Hollenberg’s research focuses on the hormonal regulation of metabolism, with a particular emphasis on the role of thyroid hormone. His work has important ramifications for the regulation of body weight and metabolism. Additionally, his laboratory focuses on understanding thyroid gland development and the possibilities for regenerative medicine.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss important recent advances in the field of thyroid cancer in 2021
  • Evaluate the most important new evidence related to thyroid dysfunction
  • Describe new data regarding thyroid physiology.
6,000 + Transsphenoidal Operations: Lessons Learned
Edward R. Laws, MD
Brigham and Women's Hospital, Boston, MA, USA
Dr. Laws received his bachelor's degree from Princeton University with honors in Economics and Sociology in the Special Program in American Civilization, and then attended the Johns Hopkins University School of Medicine in Baltimore, Maryland. He did his surgical internship and neurosurgical residency at Johns Hopkins. After completing his residency, he joined the faculty at the Johns Hopkins Medical School. In 1972, he moved to the Mayo Clinic in Rochester, Minnesota where he became Professor of Neurosurgery and developed major interests in Pituitary and Brain tumor treatment and research.  In 1987, he became Professor and Chairman of the Department of Neurosurgery at the George Washington University in Washington, DC, and in 1992 joined the faculty of the University of Virginia as Professor of Neurosurgery and Professor of Medicine, developing a Multidisciplinary Pituitary Center there. Subsequently, he was Professor of Neurosurgery at Stanford University. In 2008, he established the Pituitary/Neuroendocrine Center at Brigham and Women's Hospital, where he currently is Professor of Neurosurgery at Harvard Medical School. During his surgical career he has operated upon more than 8,000 brain tumors, of which over 6,000 have been pituitary lesions. Dr. Laws has served as President of the World Federation of Neurosurgical Societies, President of the Congress of Neurological Surgeons, Editor of Neurosurgery, President of the American Association of Neurological Surgeons, and President of the Pituitary Society. He has been the fifth neurosurgeon to become President of the American College of Surgeons and was elected to membership in the National Academy of Medicine. He remains actively involved in Brain and Pituitary tumor research and surgery.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain the objectives and technical aspects of surgery for pituitary tumors
  • Describe the pituitary tumor subtypes that are most likely to be aggressive
  • Discuss postoperative hyponatremia and its consequences
Meet the Professor: Management of Hyperthyroidism in Pregnancy
Susan J. Mandel, MD, MPH
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Recognize gestational changes in thyroid hormone physiology
  • Apply evidence-based recommendations for the treatment of maternal hyperthyroidism
  • Describe testing for potential fetal and neonatal thyrotoxicosis.
Thyroid Cancer Overdiagnosis
Julie Ann Sosa, MD, MA
University of California, San Francisco, San Francisco, CA, USA
Dr. Sosa is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is an NIH- and FDA-funded investigator and author of more than 340 peer-reviewed publications and 80 book chapters and reviews, all largely focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. She has authored or edited 7 books. Dr Sosa is Treasurer of the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines. She is the Editor-in-Chief of the World Journal of Surgery. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton, MA at Oxford, and MD at Johns Hopkins, where she completed the Halsted residency and a fellowship.

Disclosures:

Member, Data Monitoring Committee, Medullary Thyroid Cancer Consortium Registry: GlaxoSmithKline, Novo Nordisk, Astra Zeneca, Eli Lilly
Institutional Research Funding: Exelixis and Eli Lilly
 

Learning Objectives:

  • Describe the evolving epidemiology of thyroid cancer in the U.S
  • Summarize the different interpretations of the data
  • Evaluate the evidence supporting different explanations.
Meet the Professor: Challenges in the Management of Cushing's Disease
Anthony P. Heaney, MD, PhD
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
 

Learning Objectives:

  • Describe the spectrum of Cushing’s disease and its variable presentation
  • Outline the expanding therapeutic options in Cushing’s disease
  • Discuss the remaining unmet medical need and future goals.
Meet the Professor: Current Trends in Treatment of Hypopituitarism
Lisa B. Nachtigall, MD
Massachusetts General Hospital, Boston, MA, USA
Dr. Nachtigall is an Associate Professor of Medicine at Harvard Medical School, clinical director of the Neuroendocrine and Pituitary Tumor Clinical Center, director of International Programs for the Endocrine Division at Massachusetts General Hospital, and clerkship director for Neuroendocrine at Harvard Medical School. Dr. Nachtigall earned her medical degree from New York University (NYU) School of Medicine, completed her internship and residency in internal medicine at Bellevue Hospital Center/NYU school of Medicine, and a clinical fellowship in endocrinology and metabolism at Massachusetts General Hospital/Harvard Medical School. She has been published in many high impact journals, serves on the editorial board of Pituitary and has presented at many national and international medical conferences in the field of pituitary disorders.

Disclosures:

Advisory Board Member: Recordati, Strongbridge
Research Investigator: Chiasma
 

Learning Objectives:

  • Recognize the clinical presentation of hypopituitarism
  • List the biochemical tests used to diagnose hypopituitarism
  • Explain the current management of hypopituitarism.
Thyroid Tumor Board
Anne R. Cappola, MD, ScM(Moderator)
University of Pennsylvania, Philadelphia, PA, USA
Dr. Cappola is a Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism, Director of Clinical Research in the Department of Medicine, and Director of the CTSA-funded Center for Human Phenomic Science at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cappola directs an NIH-funded research program on the hormonal alterations that occur with aging and the clinical impact of these changes, with a focus on the clinical impact of subclinical thyroid dysfunction in older individuals. Dr. Cappola is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the Interurban Clinical Club and an Associate Editor for JAMA.

Disclosures:

No relevant financial relationships.
Susan J. Mandel, MD, MPH(Panelist)
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
Julie Ann Sosa, MD, MA, FACS(Panelist)
University of California, San Francisco, San Francisco, CA, USA
Dr. Sosa is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is an NIH- and FDA-funded investigator and author of more than 340 peer-reviewed publications and 80 book chapters and reviews, all largely focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. She has authored or edited 7 books. Dr Sosa is Treasurer of the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines. She is the Editor-in-Chief of the World Journal of Surgery. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton, MA at Oxford, and MD at Johns Hopkins, where she completed the Halsted residency and a fellowship.

Disclosures:

Member, Data Monitoring Committee, Medullary Thyroid Cancer Consortium Registry: GlaxoSmithKline, Novo Nordisk, Astra Zeneca, Eli Lilly
Institutional Research Funding: Exelixis and Eli Lilly
 

Learning Objectives:

  • Apply practice guideline recommendations to the management of differentiated thyroid cancer
  • Discuss the evidence that serves as the underpinning to those guidelines
  • Explain the controversies that might exist around management options.
Meet the Professor: The Thyroid and Body Weight
Anthony Hollenberg, MD
Weill Cornell Medicine, New York, NY, USA
Dr. Hollenberg is the Sanford I. Weill Chair of Medicine in the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and the Physician-in-Chief at New York-Presbyterian Hospital. Dr. Hollenberg received his M.D. from the University of Calgary in Canada in 1986. He completed his Internal Medicine residency in 1989 and was Chief Resident in Medicine from 1990 to 1991 at the Beth Israel Hospital. Dr. Hollenberg then completed a fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital in 1993 and was recruited back to Beth Israel to start his laboratory. From 2011 until his recruitment to Weill Cornell Medicine and New York-Presbyterian Hospital, Dr. Hollenberg was Chief of the Division of Endocrinology, Diabetes and Metabolism, at Beth Israel Deaconess Medical Center and Director of Clinical and Translational Research Training Programs at Harvard Catalyst and Harvard Medical School where he was also a Professor of Medicine. Dr. Hollenberg’s research focuses on the hormonal regulation of metabolism, with a particular emphasis on the role of thyroid hormone. His work has important ramifications for the regulation of body weight and metabolism. Additionally, his laboratory focuses on understanding thyroid gland development and the possibilities for regenerative medicine.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain how thyroid hormone influences human physiology
  • Describe the metabolic effects of thyroid hormone
  • Identify novel mechanisms by which thyroid hormones may regulate body weight and metabolic disease.
Update on the Management of Thyroid Nodules
Susan J. Mandel, MD, MPH
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Apply evidence-based evaluation for patients with thyroid nodules
  • Discuss the association of sonographic imaging with cancer risk and its application to FNA decision making
  • Assess the Bethesda cytology classification for reporting thyroid nodule FNA results and the indications for molecular testing.
Year in Clinical Pituitary
Anthony P. Heaney, MD, PhD
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
 

Learning Objectives:

  • Discuss the highlights in translational and clinical pituitary research in the prior year
  • Summarize and provide a critical appraisal of high impact studies in the Neuroendocrine/Pituitary field published in 2020-2021
  • Describe the practical clinical application of the published findings.
Filter below by category:

Upcoming:

Welcome and Introduction
SEP 10
11:00 AM–11:15 AM EDT
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
The Endocrinologist's Approach to Male Infertility
SEP 10
11:15 AM–12:00 PM EDT
Arthi Thirumalai, MBBS
University of Washington, Seattle, WA, USA
Dr. Thirumalai is a board-certified physician at the Endocrine and Diabetes Care Center at UWMC-Roosevelt and the Atherosclerosis/Lipid Clinic at Harborview and a UW assistant professor of Medicine and Metabolism, Endocrinology and Nutrition. Dr. Thirumalai sees a wide array of patients with general endocrine problems and diabetes. She believes the only way to succeed in helping patients with these issues is to listen to their primary concerns and see how every aspect of their lives influences their medical outcomes. Dr. Thriumalai earned her M.D. at Lady Hardinge Medical Center in New Delhi, India. She is board certified in both Internal Medicine and Endocrinology/Diabetes/Metabolism and is a member of the Endocrine Society. Dr. Thirumalai’s clinical and research interests include general endocrinology including thyroid, parathyroid, adrenal, pituitary and bone disorders, diabetes, Inpatient hyperglycemia management, male reproductive physiology and male contraception.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain the different causes of male infertility
  • Identify when to do an evaluation for endocrinologic causes of male infertility
  • Interpret the diagnostic tests of male reproductive function
  • Outline a treatment algorithm for endocrine causes of male infertility.
Master Clinician: Clinical Challenges in Secondary Osteoporosis
SEP 10
11:15 AM–12:00 PM EDT
Ann E. Kearns, MD, PhD(Moderator)
Mayo Clinic, Rochester, MN, USA
Dr. Kearns obtained her internal medicine training at the University of Chicago Hospitals, and her Endocrinology training at Massachusetts General Hospital. She joined the Mayo Clinic in Rochester, MN in 1998. She is currently the Chair of Quality and Safety in the Division of Endocrinology. Dr. Kearns has expertise in osteoporosis, calcium disorders, and metabolic bone disease. She is also involved in Quality Improvement especially in osteoporosis evaluation and management after a fracture.

Disclosures:

No relevant financial relationships.
Suzanne M. Jan de Beur, MD(Panelist)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
Benjamin Leder, MD(Panelist)
Massachusetts General Hospital, Boston, MA, USA
Dr. Leder received his medical degree from Harvard Medical School and completed his Internal Medicine Residency and Endocrine Fellowship at Massachusetts General Hospital, where he has remained ever since. His current position is Professor of Medicine at Harvard Medical School. Over the past two decades, Dr. Leder has been both an active clinician (serving as the Director of Endocrine Associates, a 16-physician practice focusing on metabolic bone disease) and clinical investigator. His NIH-funded research focuses on developing novel therapeutic approaches to the management of postmenopausal osteoporosis and other metabolic bone diseases.

Disclosures:

Advisory Board Member: Radius
Grant Recipient: Amgen
 

Learning Objectives:

  • Develop a strategy to evaluate men for secondary causes of osteoporosis
  • Utilize genetic testing in select patients to evaluate secondary causes of osteoporosis
  • Optimize nutritional factors contributing to secondary osteoporosis.
What's New in Lipid Lowering Therapies?
SEP 10
11:15 AM–12:00 PM EDT
Michael J. Blaha, MD, MPH
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Blaha (Professor of Cardiology and Epidemiology) is the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Dr. Blaha has published over 500 scientific articles, with a focus on appropriate use of tests and new therapies in the prevention of atherosclerotic cardiovascular disease. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 20 trainees, many of which have gone on to hold prominent academic appointments. Clinically, he practices as a preventive cardiologist and in the interpretation of cardiac CT. His clinic specializes in patients with advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk.

Disclosures:

Advisory Board Member: Bayer, Kaleido, Roche
Consultant: Kowa
Grant Recipient: 89Bio, Amgen, Novo Nordisk
Research Investigator: Novartis
 

Learning Objectives:

  • Discuss the mechanism of action of new lipid-lowering pharmacotherapies
  • Review the indications for newer available lipid-lowering therapies, and discuss strategies for their use in primary and secondary prevention
  • Describe the pipeline of potential future lipid-lowering therapies.
Endocrine Debate: Testosterone Therapy in Women: Never or Sometimes?
SEP 10
12:15 PM–1:00 PM EDT
Kathryn A. Martin, MD(Moderator)
Massachusetts General Hospital, Boston, MA, USA
Dr. Martin is a faculty member and practicing clinician in the Reproductive Endocrine Unit at Massachusetts General Hospital. She has an active teaching role, including the training and supervision of junior faculty members and endocrine fellows. Her research interests have been in the area of female reproduction, in particular, the pathophysiology and management of isolated GnRH deficiency and functional hypothalamic amenorrhea. She has written and lectured extensively on the evaluation and management of menopausal women. Dr. Martin has had a number of leadership roles in the Endocrine Society; she has been chair of several committees including the Nominating Committee and the Clinical Practice Guidelines committee, and she is currently a member of the Board of Directors. Dr. Martin is also the Senior Deputy Editor for Endocrinology and Patient Education, as well as a member of the GRADE/EBM group at UpToDate, an online clinical reference for physicians.

Disclosures:

Employee: UpToDate/WoltersKluwer
Susan R. Davis, MBBS, FRACP, PhD(Panelist)
Monash University, Melbourne, VIC, Australia
Dr. Davis is an NHMRC Senior Principal Research Fellow, Director, Monash University Women’s Health Research Program, Consultant Endocrinologist and Head, Specialist Women’s Health Clinic, Alfred Hospital Melbourne and consultant at Cabrini Medical Centre. Her research has advanced the understanding of estrogen and testosterone action, deficiency and replacement in women. She is a past president of the Australasian Menopause Society and immediate past President of the International Menopause Society. She has over 420 peer-reviewed publications and in numerous awards. In 2021 Prof Davis was appointed an Officer of the Order of Australia distinguished service to medicine, to women's health as a clinical endocrinologist and researcher, and to medical education.

Disclosures:

Advisory Board Member: Mayne Pharmaceuticals, Theramex
Consultant: Lawley Pharm, Que Oncology
Speaker: BioFemme, Besins Healthcare
Margaret E. Wierman, MD(Panelist)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Wierman is a Professor of Medicine, Integrative Physiology at the University of Colorado School of Medicine. She directs the Pituitary and Adrenal Tumor Program. Dr. Wierman is a translational physician scientist whose research interest has been in reproductive endocrinology and sex hormone action, and more recently in the molecular mechanisms of pituitary tumors and adrenal cancer. She has led many committees in the Endocrine Society and is Past Clinical Scientist Vice President. She directs the Program to Advance Gender Equity in the Department of Medicine at the University of Colorado. Dr. Wierman has a long track record in mentoring and pipeline development of academic researchers. She received the Women in Endocrinology Mentor Award and the Endocrine Society Laureate Mentor Award from the Endocrine Society. Dr. Wierman is currently the Chair of the International Society of Endocrinology

Disclosures:

Research Investigator: Corcept, Novo Nordisk
 

Learning Objectives:

  • Describe the assessment for possible testosterone therapy in post-menopausal women
  • Describe the indications for androgen therapy in women
  • Describe the data about the risk of androgen therapy in women for hypoactive sexual desire disorder.
Meet the Professor: Calcium Conundrums
SEP 10
12:15 PM–1:00 PM EDT
Ann E. Kearns, MD, PhD(Panelist)
Mayo Clinic, Rochester, MN, USA
Dr. Kearns obtained her internal medicine training at the University of Chicago Hospitals, and her Endocrinology training at Massachusetts General Hospital. She joined the Mayo Clinic in Rochester, MN in 1998. She is currently the Chair of Quality and Safety in the Division of Endocrinology. Dr. Kearns has expertise in osteoporosis, calcium disorders, and metabolic bone disease. She is also involved in Quality Improvement especially in osteoporosis evaluation and management after a fracture.

Disclosures:

No relevant financial relationships.
Suzanne M. Jan de Beur, MD(Panelist)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
 

Learning Objectives:

  • Describe pathophysiology of basic mineral metabolism
  • Recognize the clinical presentation of disorders of hypo and hypercalcemia
  • Discuss how to optimize regimens for hypocalcemia.
Meet the Professor: When is a Lipid Panel Not Enough?
SEP 10
12:15 PM–1:00 PM EDT
Michael J. Blaha, MD, MPH
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Blaha (Professor of Cardiology and Epidemiology) is the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Dr. Blaha has published over 500 scientific articles, with a focus on appropriate use of tests and new therapies in the prevention of atherosclerotic cardiovascular disease. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 20 trainees, many of which have gone on to hold prominent academic appointments. Clinically, he practices as a preventive cardiologist and in the interpretation of cardiac CT. His clinic specializes in patients with advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk.

Disclosures:

Advisory Board Member: Bayer, Kaleido, Roche
Consultant: Kowa
Grant Recipient: 89Bio, Amgen, Novo Nordisk
Research Investigator: Novartis
 

Learning Objectives:

  • Describe the role of other markers of CVD risk such as lipoprotein(a), apoB and hsCRP
  • Review the guidelines for measuring and using Coronary Artery Calcium scores
  • Explain the role of lipid-lowering therapies in the setting of elevated non-traditional markers of CVD risk.
T Test: What is the Best Test?
SEP 10
1:15 PM–2:00 PM EDT
Shehzad Basaria, MD
Brigham and Women's Hospital, Boston, MA, USA
Dr. Basaria is Professor of Medicine at Harvard Medical School/Brigham and Women's Hospital, and Associate Director of the Section of Men's Health, Aging and Metabolism. His clinical and research interests are in the field of Male Reproduction. His work focuses on cardiometabolic complications of androgen deprivation therapy in men with prostate cancer and the efficacy of testosterone replacement in men with opioid-induced androgen deficiency.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the criteria for the diagnosis of the male hypogonadism
  • Identify what laboratory tests should be used to diagnose male hypogonadism
  • Explain the controversy about the value of assessment of total testosterone versus free testosterone in the diagnosis of male hypogonadism.
  • Discuss how medical conditions and medications influence serum sex steroid concentrations.
Updates in Osteoporosis Treatment
SEP 10
1:15 PM–2:00 PM EDT
Benjamin Leder, MD
Massachusetts General Hospital, Boston, MA, USA
Dr. Leder received his medical degree from Harvard Medical School and completed his Internal Medicine Residency and Endocrine Fellowship at Massachusetts General Hospital, where he has remained ever since. His current position is Professor of Medicine at Harvard Medical School. Over the past two decades, Dr. Leder has been both an active clinician (serving as the Director of Endocrine Associates, a 16-physician practice focusing on metabolic bone disease) and clinical investigator. His NIH-funded research focuses on developing novel therapeutic approaches to the management of postmenopausal osteoporosis and other metabolic bone diseases.

Disclosures:

Advisory Board Member: Radius
Grant Recipient: Amgen
 

Learning Objectives:

  • Recognize potential causes and contributors to the current crises in osteoporosis care
  • Assess the relative efficacy and limitations of anabolic and antiresorptive osteoporosis therapies
  • Summarize the relative efficacy of various sequential and combination approaches to osteoporosis management.
What the Endocrinologist Needs to Know About the Diagnosis and Management of Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
SEP 10
1:15 PM–2:00 PM EDT
Kenneth Cusi, MD
University of Florida, Gainesville, FL, USA
Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville, and at the Veterans Administration Medical Center at Gainesville, FL (2011-present). He completed his medical training and residency in Buenos Aires, Argentina, and fellowship in endocrinology at Baylor College of Medicine, Houston, Texas. He worked after his training at the University of San Antonio Health Science Center, Texas (1992-2011) on the role of defects in insulin secretion/insulin resistance in the development of T2DM and later focused on the underlying mechanisms and new treatments for nonalcoholic fatty liver disease (NAFLD) in T2DM. Dr. Cusi has published over 200 original articles, editorials, reviews and book chapters in the fields of diabetes, obesity and liver disease. He has contributed to several guidelines in NAFLD. His basic and clinical research programs in diabetes and fatty liver disease include funding from the NIH and from industry examining new treatments for NASH. The University of Florida awarded him in 2015 two awards, the Exemplary Teacher Award and the Clinical Research Award for Outstanding Achievement, Research Discovery, and Productivity. In 2020, he received the American Association of Clinical Endocrinologists (AACE) Jack Baskin, MD, Endocrine Teaching Award.

Disclosures:

Advisory Board Member: Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal
Research Investigator: Echosens, Inventiva, Novo Nordisk, Poxel, Zydus
 

Learning Objectives:

  • Recognize the magnitude of the problem and the mechanisms leading to steatohepatitis in patients with obesity and type 2 diabetes mellitus
  • Compare the diagnostic tools available for NAFLD and hepatic fibrosis and select the best tools for your practice
  • Evaluate current treatment modalities for steatohepatitis, both as monotherapy and in combination, and for the management of associated comorbidities (obesity, insulin resistance, dyslipidemia, CVD).
Disorders of Phosphate
SEP 10
2:15 PM–3:00 PM EDT
Suzanne M. Jan de Beur, MD
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
 

Learning Objectives:

  • Discuss hormonal regulation phosphate homeostasis
  • Explain the differential diagnosis of hypophosphatemia and hyperphosphatemia based on clinical and biochemical characteristic
  • Describe new treatment options for some forms of FGF23 mediated hypophosphatemia.
Master Clinician: Alopecia in Women: The Endocrinologist's Approach
SEP 10
2:15 PM–3:00 PM EDT
Margaret E. Wierman, MD(Moderator)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Wierman is a Professor of Medicine, Integrative Physiology at the University of Colorado School of Medicine. She directs the Pituitary and Adrenal Tumor Program. Dr. Wierman is a translational physician scientist whose research interest has been in reproductive endocrinology and sex hormone action, and more recently in the molecular mechanisms of pituitary tumors and adrenal cancer. She has led many committees in the Endocrine Society and is Past Clinical Scientist Vice President. She directs the Program to Advance Gender Equity in the Department of Medicine at the University of Colorado. Dr. Wierman has a long track record in mentoring and pipeline development of academic researchers. She received the Women in Endocrinology Mentor Award and the Endocrine Society Laureate Mentor Award from the Endocrine Society. Dr. Wierman is currently the Chair of the International Society of Endocrinology

Disclosures:

Research Investigator: Corcept, Novo Nordisk
Andrea Kalus, MD(Panelist)
University of Washington, Seattle, WA, USA
Dr. Kalus, co-directs the Rheumatology-Dermatology Clinic at the UW Roosevelt Clinic. Her clinical practice focuses on autoimmune diseases, complex medical dermatology and phototherapy. Dr. Kalus earned her M.D. at the University of Washington. She completed residency training in both internal medicine and dermatology. Dr. Kalus partners with multidisciplinary research teams to study lupus, dermatomyositis and skin manifestations of systemic disease.

Disclosures:

Grant Recipient: Janssen, Lilly
Kathryn A. Martin, MD(Panelist)
Massachusetts General Hospital, Boston, MA, USA
Dr. Martin is a faculty member and practicing clinician in the Reproductive Endocrine Unit at Massachusetts General Hospital. She has an active teaching role, including the training and supervision of junior faculty members and endocrine fellows. Her research interests have been in the area of female reproduction, in particular, the pathophysiology and management of isolated GnRH deficiency and functional hypothalamic amenorrhea. She has written and lectured extensively on the evaluation and management of menopausal women. Dr. Martin has had a number of leadership roles in the Endocrine Society; she has been chair of several committees including the Nominating Committee and the Clinical Practice Guidelines committee, and she is currently a member of the Board of Directors. Dr. Martin is also the Senior Deputy Editor for Endocrinology and Patient Education, as well as a member of the GRADE/EBM group at UpToDate, an online clinical reference for physicians.

Disclosures:

Employee: UpToDate/WoltersKluwer
 

Learning Objectives:

  • Describe the pathophysiology of common causes of alopecia in women
  • Diagnose female pattern hair loss.
  • Recognize the clinical features and diagnostic approach to scarring and non-scarring hair loss
  • Identify the diagnostic evaluation for endocrinopathies in women who have alopecia.
  • Discuss the treatment options for common causes of alopecia in women.
Meet the Professor: Overcoming Barriers to Obesity Therapy, a Case-Based Approach
SEP 10
2:15 PM–3:00 PM EDT
Ania M. Jastreboff, MD, PhD
Yale School of Medicine, New Haven, CT, USA
Dr. Jastreboff is an Associate Professor of Internal Medicine & Pediatrics (Endocrinology & Pediatric Endocrinology) at Yale University School of Medicine, Director of Weight Management and Obesity Prevention at the Yale Stress Center, and co-Director of the Yale Center for Weight Management. After completing a Med/Peds Residency, Dr. Jastreboff completed a dual fellowship in both Adult Endocrinology and Pediatric Endocrinology during which she also completed a PhD in the neurobiology of obesity, becoming board certified in Obesity Medicine, Adult Endocrinology, and Pediatric Endocrinology. Dr. Jastreboff is a clinically active physician-scientist nationally and internationally recognized for helping to develop the 2016 Clinical Practice Guidelines for The Comprehensive Care of Patients with Obesity (AACE/ACE), educating the next generation of Obesity Medicine physicians by teaching annually at the Harvard Blackburn Treating Obesity course, the Columbia/Cornell Obesity course, selected international courses, and conducting cutting-edge clinical translational obesity research. Her research includes both large, multi-center clinical outcomes trials using anti-obesity medication as well as neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and the mechanisms of anti-obesity medications. Dr. Jastreboff's research is supported by NIH/NIDDK (K23, R01s), American Diabetes Association (ADA), and industry funded multi-center clinical trials. Nationally, she serves as the vice-Chair of the Clinical Care Committee of The Obesity Society (TOS) and has been selected to serve as a Director on the American Board of Obesity Medicine (ABOM). Clinically, Dr. Jastreboff specializes in sophisticated use of anti-obesity medication combinations to help patients reach their weight and health goals.

Disclosures:

Consultant: Boehringer Ingelheim, Eli Lilly, Novo Nordisk
Grant Recipient: American Diabetes Association, NIH/NIDDK
Site-PI for Multi-Center Trial: Eli Lilly, Novo Nordisk
 

Learning Objectives:

  • Identify and overcome barriers to treating obesity
  • Become familiar with available anti-obesity medications and key concepts in their use for treating patients with obesity
  • Understand the importance of comprehensive care for individuals with obesity.
Ancillary Symposium: Challenges in Diagnosing and Managing Patients with Fibrodysplasia Ossificans Progressiva
SEP 10
3:10 PM–4:40 PM EDT
Welcome and Introduction
Kelly L. Wentworth, MD
University of California, San Francisco, San Francisco, CA, USA
Dr. Wentworth is an Assistant Professor in the Department of Medicine, Division of Endocrinology at Zuckerberg San Francisco General Hospital, University of California, San Francisco. She has a clinical and research interest in metabolic bone disorders, with a specific focus on fibrous dysplasia/McCune-Albright Syndrome and fibrodysplasia ossificans progressiva (FOP).  She is currently funded by an NIH/NIDCR K08 career development grant.

Disclosures:

Research Investigator: Ipsen pharmaceuticals
Clinical Presentation and Treatment Options for Patients with FOP
Mona Al Mukaddam, MD, MS(Panelist)
Penn Medicine University City, Philadelphia, PA, USA
Dr. Al Mukaddam is an adult endocrinologist in the Division of Endocrinology, Diabetes and Metabolism at the Pennsylvania and Director of the Penn Bone Center. Dr. Al Mukaddam received her Bachelor of Science and Medical Degrees from American University in Beirut, Lebanon. She completed her internship and residency in internal medicine at the University of Iowa, a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Penn, and received a Master of Science Degree in translational medicine and therapeutics at the University of Pennsylvania. Dr. Al Mukaddam is board certified in endocrinology, diabetes and metabolism. She is the principal investigator on ongoing clinical trials in FOP at the Center for Research in FOP & Related Disorders at Penn and is a founding member of the International Clinical Council on FOP (ICC).

Disclosures:

Research Investigator: Clementia/Ipsen Pharmaceuticals, Regeneron
Elisabeth M.W. Eekhoff, MD, PhD(Panelist)
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Basic and Translational Science Advancements in FOP
Benjamin Levi, MD
UT Southwestern Medical Center, Boston, MA, USA
Dr. Levi holds the Dr. Lee Hudson-Robert R. Penn Chair in Surgery and Plastic and Reconstructive Surgery and serves as Chief of the Division of Burn, Trauma, Acute and Critical Care Surgery. He specializes in acute and reconstructive burn surgery and scar reconstructive surgery. Certified by the American Board of Plastic Surgery and the American Board of Surgery, Dr. Levi joined the UT Southwestern faculty in 2020. Previously, he was Director of the Burn/Wound and Regenerative Medicine Laboratory and Associate Director of Burn Surgery Service at the University of Michigan. Dr. Levi’s research interests, which are funded by the National Institutes of Health, the American College of Surgeons, and the Department of Defense, include stem cell biology, heterotopic ossification, muscle fibrosis, tissue regeneration, wound healing and repair, and burn reconstruction outcomes.

Disclosures:

No relevant financial relationships.
Future Management Options for Patients with FOP
Elisabeth M.W. Eekhoff, MD, PhD
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Post-test, Panel Discussion, and Q&A
Kelly L. Wentworth, MD(Moderator)
University of California, San Francisco, San Francisco, CA, USA
Dr. Wentworth is an Assistant Professor in the Department of Medicine, Division of Endocrinology at Zuckerberg San Francisco General Hospital, University of California, San Francisco. She has a clinical and research interest in metabolic bone disorders, with a specific focus on fibrous dysplasia/McCune-Albright Syndrome and fibrodysplasia ossificans progressiva (FOP).  She is currently funded by an NIH/NIDCR K08 career development grant.

Disclosures:

Research Investigator: Ipsen pharmaceuticals
Mona Al Mukaddam, MD, MS(Panelist)
Penn Medicine University City, Philadelphia, PA, USA
Dr. Al Mukaddam is an adult endocrinologist in the Division of Endocrinology, Diabetes and Metabolism at the Pennsylvania and Director of the Penn Bone Center. Dr. Al Mukaddam received her Bachelor of Science and Medical Degrees from American University in Beirut, Lebanon. She completed her internship and residency in internal medicine at the University of Iowa, a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Penn, and received a Master of Science Degree in translational medicine and therapeutics at the University of Pennsylvania. Dr. Al Mukaddam is board certified in endocrinology, diabetes and metabolism. She is the principal investigator on ongoing clinical trials in FOP at the Center for Research in FOP & Related Disorders at Penn and is a founding member of the International Clinical Council on FOP (ICC).

Disclosures:

Research Investigator: Clementia/Ipsen Pharmaceuticals, Regeneron
Elisabeth M.W. Eekhoff, MD, PhD(Panelist)
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Benjamin Levi, MD(Panelist)
UT Southwestern Medical Center, Boston, MA, USA
Dr. Levi holds the Dr. Lee Hudson-Robert R. Penn Chair in Surgery and Plastic and Reconstructive Surgery and serves as Chief of the Division of Burn, Trauma, Acute and Critical Care Surgery. He specializes in acute and reconstructive burn surgery and scar reconstructive surgery. Certified by the American Board of Plastic Surgery and the American Board of Surgery, Dr. Levi joined the UT Southwestern faculty in 2020. Previously, he was Director of the Burn/Wound and Regenerative Medicine Laboratory and Associate Director of Burn Surgery Service at the University of Michigan. Dr. Levi’s research interests, which are funded by the National Institutes of Health, the American College of Surgeons, and the Department of Defense, include stem cell biology, heterotopic ossification, muscle fibrosis, tissue regeneration, wound healing and repair, and burn reconstruction outcomes.

Disclosures:

No relevant financial relationships.
supported by:
This program is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.
 

Learning Objectives:

  • Analyze clinical presentations of FOP in individuals
  • Review the importance of early diagnosis and management of FOP
  • Describe the best practices in the diagnosis and management of patients with FOP
Welcome and Introduction
SEP 11
10:55 AM–11:00 AM EDT
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
Automated Insulin Delivery in the Management of T1DM
SEP 11
11:00 AM–11:45 AM EDT
Anne L. Peters, MD
University of Southern California, Los Angeles, CA, USA
Dr. Peters is a Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes programs at Cedars-Sinai and UCLA. Her research has focused on testing new approaches for diagnosing and treating diabetes and developing systems of care to improve outcomes in diabetic populations. She has published over 200 articles, reviews, and abstracts and three books on diabetes. She has been an investigator on over 40 research studies and has spoken at over 400 programs throughout the US as well as internationally. She has served on many committees for the ADA and other organizations. Currently she is the chair of the Endocrine Society Committee on Diabetes Devices and is on the EASD/ADA Technology Safety Committee. Additionally she is a member of the JDRF Panel on Management of Exercise in Type 1 Diabetes. She is a member of the ABIM Endocrinology Subspecialty Board. She consults for many entities, including the FDA, Optum Rx and CVS/Caremark to help guide the development and use of treatments for diabetes.

Disclosures:

Advisory Board Member: Eli Lilly, Novo Nordisk, Zealand
Research Investigator: Abbot Diabetes Care, Dexcom, Insulet
Stock Options: Omada Health, Teladoc
 

Learning Objectives:

  • Review the strengths of hybrid closed loop technology
  • Summarize the weaknesses of hybrid closed loop technology
  • Identify patients who would benefit most from closed-loop technologies and those for whom it may not be appropriate.
Master Clinician: CKD and Diabetes: Management of Diabetes in Patients with Progressive CKD
SEP 11
11:00 AM–11:45 AM EDT
Rita R. Kalyani, MD, MHS(Moderator)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Kalyani is an Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at Johns Hopkins University School of Medicine. She graduated with an undergraduate degree from Harvard College and completed her medical degree, residency, and fellowship at Johns Hopkins. Dr. Kalyani is an active clinician and sees patients regularly in the Johns Hopkins Comprehensive Diabetes Center. She directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program. A recipient of NIH grant funding, Dr. Kalyani's research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases. She has served on the editorial boards of several diabetes research journals and has authored more than 125 peer-reviewed publications. Dr. Kalyani is a past Chair of the American Diabetes Association’s Professional Practice Committee which is responsible for the annual clinical guidelines statement, “ADA Standards of Medical Care in Diabetes”. She is the Editor-in-Chief of the Johns Hopkins Patient Guide to Diabetes website. Dr. Kalyani currently serves on the Clinical Guidelines Committee for the Endocrine Society.

Disclosures:

No relevant financial relationships.
Silvio E. Inzucchi, MD(Panelist)
Yale School of Medicine, New Haven, CT, USA
Dr. Inzucchi is a Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center. He is well known as an author and lecturer in diabetes management for more than two decades. He served as co-chair of the ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes and has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.

Disclosures:

Advisory Board Member: Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Lexicon, Merck, Novo Nordisk, VTV Therapeutics
Consultant: Abbott, Esperion, Merck, vTv Therapeutics
Speaker: AstraZeneca, Boehringer Ingelheim
Clinical Trial Publications Committee Member: Boehringer Ingelheim
Clinical Trial Executive Committee Member: AstraZeneca
Clinical Trial Steering Committee Member: Novo Nordisk
Robert C. Stanton, MD(Panelist)
Joslin Diabetes Center, Boston, MA, USA
Dr. Stanton is Chief of the Kidney and Hypertension Section at the Joslin Diabetes Center, a Principal Investigator (Section on Vascular Cell Biology), and an Associate Professor of Medicine at Harvard Medical School. Dr. Stanton has given many invited lectures throughout the world and written many original articles and reviews on clinical and basic science aspects of diabetic kidney disease. Dr. Stanton’s research is focused on the essential enzyme, glucose 6-phosphate dehydrogenase (G6PD). His lab has discovered that this enzyme (and associated pathway) is essential for cell survival and dysregulation of G6PD plays an important role in the pathogenesis of many diseases. He has received honorary professorships from other universities and a major lifetime-achievement teaching award for Sustained Excellence in Teaching from Harvard Medical School.

Disclosures:

Advisory Board Member: Bayer Pharmaceuticals
 

Learning Objectives:

  • Discuss the renoprotection of new antihyperglycemic agents
  • Describe safe use of antihyperglycemic medications in patients with kidney disease
  • Identify clinical trials demonstrating that specific antihyperglycemic drugs delay the progression of kidney disease.
Meet the Professor: Tips for Clinicians for Genetic Evaluations of Adrenal Disorders
SEP 11
11:00 AM–11:45 AM EDT
Lauren Fishbein, MD, PhD
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Fishbein is an Associate Professor at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes. She earned an MD, PhD degree from the University of Florida, and completed Internal Medicine Residency at Harvard’s Beth Israel Deaconess Medical Center and Endocrinology Fellowship at the University of Pennsylvania. Her research and clinical interests are in neuroendocrine tumor genetics. Dr. Fishbein has a strong interest in personalized medicine including understanding the impact of germline predisposition genetics, as well as understanding neuroendocrine tumor development and metastatic disease. Dr. Fishbein is a member of the Endocrine Society’s Annual Meeting Steering Committee and previously served as co-chair of the Trainee and Career Development Core Committee.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify when to refer a patient with an adrenal tumor for clinical genetic testing
  • List genetic predisposition syndromes associated with adrenal tumor.
  • Describe how to screen patients with hereditary predisposition for pheochromocytoma/paraganglioma.
Health Disparities in Diabetes
SEP 11
12:00 PM–12:45 PM EDT
Rocio I. Pereira, MD
Denver Health, Denver, CO, USA
Dr. Pereira is the Chief of Endocrinology at Denver Health, Associate Professor of Medicine at the University of Colorado, Division of Endocrinology, Metabolism, and Diabetes, and the Founder and Director of the Vuela for Health lifestyle intervention program for Latino immigrants. The primary focus of Dr. Pereira’s work is addressing health disparities in diabetes and obesity. Dr. Pereira has been a member of the Endocrine Society since 2001. She has served as Chair of the Minority Affairs Committee/Committee on Diversity and Inclusion (CODI), and contributed to a number of other Society efforts. Dr. Pereira is currently a member of the Board of Directors, Board representative to CODI, and the Program Director for the upcoming EXCEL- Excellence in Clinical Endocrinology and Leadership program.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Summarize the nature and extent of disparities in diabetes affecting national and global racial and ethnic minority communities
  • Recognize systemic racism as the fundamental underlying cause of health disparities
  • Apply knowledge of health equity best practices to identify actions to address health disparities.
Meet the Professor: Management of Adrenal Tumors in Pregnancy
SEP 11
12:00 PM–12:45 PM EDT
William F. Young Jr., MD, MSc
Mayo Clinic, Rochester, MN, USA
Dr. Young is the Tyson Family Endocrinology Clinical Professor and Professor of Medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minnesota, USA. He is the recipient of multiple education awards and is a past president of the Endocrine Society and past chair of the Division of Endocrinology at Mayo Clinic. Dr. Young’s clinical research focuses on primary aldosteronism and pheochromocytoma. He has published more than 300 articles on endocrine hypertension and adrenal and pituitary disorders. He has delivered more than 650 presentations at national and international meetings and he has been an invited visiting professor for more than 150 medical institutions.

Disclosures:

Adrenal Safety Monitor for Progesterone Receptor Modulator Trial: Bayer
 

Learning Objectives:

  • Discuss treatment options for the woman with a catecholamine-secreting tumor diagnosed during pregnancy
  • Review the potential effects of pregnancy on underlying primary aldosteronism and impact on treatment decisions
  • Determine the most likely cause for Cushing syndrome during pregnancy to direct optimal management.
Meet the Professor: Pancreatogenic Diabetes
SEP 11
12:00 PM–12:45 PM EDT
Rita R. Kalyani, MD, MHS
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Kalyani is an Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at Johns Hopkins University School of Medicine. She graduated with an undergraduate degree from Harvard College and completed her medical degree, residency, and fellowship at Johns Hopkins. Dr. Kalyani is an active clinician and sees patients regularly in the Johns Hopkins Comprehensive Diabetes Center. She directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program. A recipient of NIH grant funding, Dr. Kalyani's research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases. She has served on the editorial boards of several diabetes research journals and has authored more than 125 peer-reviewed publications. Dr. Kalyani is a past Chair of the American Diabetes Association’s Professional Practice Committee which is responsible for the annual clinical guidelines statement, “ADA Standards of Medical Care in Diabetes”. She is the Editor-in-Chief of the Johns Hopkins Patient Guide to Diabetes website. Dr. Kalyani currently serves on the Clinical Guidelines Committee for the Endocrine Society.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss the relationship of pancreatic disease to the development of diabetes
  • Describe the different etiologies for pancreatogenic diabetes
  • Outline unique considerations in diabetes management in pancreatogenic diabetes.
Important and Practice-Changing Publications in Diabetes, 2021
SEP 11
1:00 PM–1:45 PM EDT
Silvio E. Inzucchi, MD
Yale School of Medicine, New Haven, CT, USA
Dr. Inzucchi is a Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center. He is well known as an author and lecturer in diabetes management for more than two decades. He served as co-chair of the ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes and has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.

Disclosures:

Advisory Board Member: Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Lexicon, Merck, Novo Nordisk, VTV Therapeutics
Consultant: Abbott, Esperion, Merck, vTv Therapeutics
Speaker: AstraZeneca, Boehringer Ingelheim
Clinical Trial Publications Committee Member: Boehringer Ingelheim
Clinical Trial Executive Committee Member: AstraZeneca
Clinical Trial Steering Committee Member: Novo Nordisk
 

Learning Objectives:

  • Summarize key findings from recent practice-changing publications in diabetes
  • Explain the context of recent important publications in diabetes
  • Outline potential implications of recent key publications in diabetes.
Master Clinician: Chromaffin Tumors Perspectives
SEP 11
1:00 PM–1:45 PM EDT
Lauren Fishbein, MD, PhD(Moderator)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Fishbein is an Associate Professor at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes. She earned an MD, PhD degree from the University of Florida, and completed Internal Medicine Residency at Harvard’s Beth Israel Deaconess Medical Center and Endocrinology Fellowship at the University of Pennsylvania. Her research and clinical interests are in neuroendocrine tumor genetics. Dr. Fishbein has a strong interest in personalized medicine including understanding the impact of germline predisposition genetics, as well as understanding neuroendocrine tumor development and metastatic disease. Dr. Fishbein is a member of the Endocrine Society’s Annual Meeting Steering Committee and previously served as co-chair of the Trainee and Career Development Core Committee.

Disclosures:

No relevant financial relationships.
Anand Vaidya, MD, MMSc(Panelist)
Brigham and Women's Hospital, Boston, MA, USA
Dr. Vaidya is currently the Director of the Center for Adrenal Disorders at Brigham and Women’s Hospital and an Associate Professor at Harvard Medical School. He oversees the multi-disciplinary clinical care of patients with adrenal diseases and runs a translational research program. His research has helped characterize and redefine the severity spectrum of primary aldosteronism, the optimal approaches to treating primary aldosteronism, the genetics of pheochromocytoma-paraganglioma syndromes, and the systemic consequences of adrenal tumors and hypercortisolism. Dr. Vaidya is a dedicated educator; he is the director of the pre-clerkship endocrinology curriculum at HMS, he directs the interactive medical case series for the New England Journal of Medicine, and he regularly teaches clinical audiences about updates in adrenal diseases.

Disclosures:

Advisory Board Member: Mineralys
Consultant: Corcept, HRA Pharma
William F. Young Jr., MD, MSc(Panelist)
Mayo Clinic, Rochester, MN, USA
Dr. Young is the Tyson Family Endocrinology Clinical Professor and Professor of Medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minnesota, USA. He is the recipient of multiple education awards and is a past president of the Endocrine Society and past chair of the Division of Endocrinology at Mayo Clinic. Dr. Young’s clinical research focuses on primary aldosteronism and pheochromocytoma. He has published more than 300 articles on endocrine hypertension and adrenal and pituitary disorders. He has delivered more than 650 presentations at national and international meetings and he has been an invited visiting professor for more than 150 medical institutions.

Disclosures:

Adrenal Safety Monitor for Progesterone Receptor Modulator Trial: Bayer
 

Learning Objectives:

  • Describe how to do work up a patient with elevated catecholamines/metanephrines
  • Describe pitfalls of imaging and biochemical studies in the diagnosis of pheochromocytoma/paraganglioma
  • Select which imaging study is best for identifying pheochromocytoma/paraganglioma.
Utility of Adrenal Androgens in Clinical Practice
SEP 11
1:00 PM–1:45 PM EDT
Adina F. Turcu, MD, MS
University of Michigan, Ann Arbor, MI, USA
Dr. Turcu is an Assistant Professor of Internal Medicine at University of Michigan, Ann Arbor. Dr. Turcu completed her Endocrinology fellowship at Mayo Clinic, Rochester, MN, and subsequently pursued a postdoctoral fellowship with focus on adrenal pathophysiology and steroid biology at the University of Michigan. Dr. Turcu’s research focuses on primary aldosteronism, congenital adrenal hyperplasia, Cushing syndrome, and adrenal androgenesis across ages. She has expertise in mass spectrometry and has a particular interest in identifying novel biomarkers with clinical relevance in adrenal disorders. Dr. Turcu’s research is currently supported by the NIH and by a Doris Duke Foundation Clinical Scientist Development Award. Dr. Turcu is the recipient of numerous prestigious awards, such as the Mayo Clinic Randall G. Sprague Award for outstanding clinical, investigative, and academic achievement in Endocrinology; the Women in Endocrinology Young Investigator Award; the Endocrine Society Early Investigators Award; and the ASCI's 2020 Young Physician-Scientist Awards.

Disclosures:

Advisory Board Member: CinCor
Consultant: Chiasma, Crinetics, PhaseBio, Poxel
 

Learning Objectives:

  • Discuss physiological sources of androgens, with emphasis on adrenal androgens
  • Identify the clinical utility of adrenal androgens in the diagnosis and management of disorders of androgens excess (Congenital adrenal hyperplasia, PCOS, Premature adrenarche)
  • Identify the clinical utility of adrenal androgens in assessing the hypothalamic-pituitary-adrenal axis (adrenal insufficiency and autonomous hypercortisolism).
Meet the Professor: Facing the Challenges of Severe Insulin Resistance
SEP 11
2:00 PM–2:45 PM EDT
Anastassia Amaro, MD
University of Pennsylvania, Philadelphia, PA, USA
Dr. Amaro is an Associate Professor of Clinical Medicine in the Division of Endocrinology and Metabolism at the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Amaro, a graduate from Sechenov Moscow Medical Academy in Moscow, Russia, completed her residency in Internal Medicine at Lutheran General Hospital in Chicago, Illinois. Her fellowship training in Endocrinology and Metabolism was at Washington University and at the Barnes-Jewish Hospital in St. Louis, Missouri. Double-boarded in Endocrinology and Obesity Medicine, Dr. Amaro established Penn Metabolic Medicine (PMM) center and has been serving as the Medical Director of PMM since 2015. Penn Metabolic Medicine is a unique translational clinic dedicated to clinical care and research in subjects with obesity and abnormalities of carbohydrate metabolism. Dr. Amaro serves as an investigator on several clinical trials in obesity and diabetes.

Disclosures:

Advisory Board Member: Novo Nordisk
Research Investigator: Fractyl Laboratories, Inc.
 

Learning Objectives:

  • Summarize current medical knowledge of mechanisms of insulin resistance at various tissue levels
  • Discuss the therapeutic challenges of severe insulin resistance
  • Identify clinical strategies for maintaining glycemic control in severely insulin resistant patients.
Prevention and Management of Hypoglycemia
SEP 11
2:00 PM–2:45 PM EDT
Kasia J. Lipska, MD, MHS
Yale School of Medicine, New Haven, CT, USA
Dr. Lipska is an Associate Professor of Medicine (Endocrinology) at the Yale School of Medicine and a Clinical Investigator at the Yale-New Haven Hospital Center for Outcomes Research and Evaluation (CORE). She received her medical degree from Harvard Medical School, completed internal medicine residency at the Brigham and Women’s Hospital, and her endocrine training at the Yale School of Medicine, where she also received a Masters degree in Health Science through the Robert Wood Johnson Clinical Scholars Program. Currently, she cares for patients at the Yale Diabetes Center, directs an NIH-funded research program focused on improving the safety and effectiveness of treatment of type 2 diabetes mellitus, and mentors students, trainees, and early stage faculty in diabetes outcomes research.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify risk factors for hypoglycemia
  • Describe strategies to reduce the risk of hypoglycemia
  • Outline the available treatments for hypoglycemia including newer formulations of glucagon.
Primary Aldosteronism: Once a Zebra, Now a Horse
SEP 11
2:00 PM–2:45 PM EDT
Anand Vaidya, MD, MMSc
Brigham and Women's Hospital, Boston, MA, USA
Dr. Vaidya is currently the Director of the Center for Adrenal Disorders at Brigham and Women’s Hospital and an Associate Professor at Harvard Medical School. He oversees the multi-disciplinary clinical care of patients with adrenal diseases and runs a translational research program. His research has helped characterize and redefine the severity spectrum of primary aldosteronism, the optimal approaches to treating primary aldosteronism, the genetics of pheochromocytoma-paraganglioma syndromes, and the systemic consequences of adrenal tumors and hypercortisolism. Dr. Vaidya is a dedicated educator; he is the director of the pre-clerkship endocrinology curriculum at HMS, he directs the interactive medical case series for the New England Journal of Medicine, and he regularly teaches clinical audiences about updates in adrenal diseases.

Disclosures:

Advisory Board Member: Mineralys
Consultant: Corcept, HRA Pharma
 

Learning Objectives:

  • Identify primary aldosteronism as a highly prevalent and unrecognized syndrome that manifests across a continuum of severity
  • Describe how to recalibrate diagnostic interpretations to maximize diagnosis and treatment
  • Recognize how primary aldosteronism syndrome contributes to the pathogenesis of a large proportion of “idiopathic” hypertension and cardiovascular disease.
Ancillary Symposium: New Heights in Growth Hormone Deficiency: Advancements in Adult Patient Care
SEP 11
2:55 PM–3:55 PM EDT
Welcome and Introduction
John D. Carmichael, MD
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Unique Diagnostic Challenges in Adult GHD
John D. Carmichael, MD
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Current, New, and Emerging GHD Therapeutic Options
Nicholas A. Tritos, MD, DSc
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Dr. Tritos is a staff neuroendocrinologist in the Neuroendocrine and Pituitary Tumor Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital (MGH) in Boston. He completed medical studies at The University of Athens (MD, DSc) and at Harvard Medical School (MMSc) where he now serves as Associate Professor of Medicine. Dr. Tritos completed his postgraduate medical training at Beth Israel Medical Center in Boston and received board certifications from the American Board of Internal Medicine in Endocrinology, Diabetes and Metabolism and Internal Medicine. Dr. Tritos’ main clinical and research interests include pituitary disease, growth hormone deficiency in adults and regulation of energy homeostasis. He mainly conducts clinical research focusing on pituitary tumors and growth hormone deficiency in adults. Dr. Tritos has served on the Curriculum Committee at Tufts University School of Medicine, currently serves as Chair of the Endocrine Fellowship Curriculum Committee, is a member of the Institutional Review Board and the Clinical Competency Committee at MGH, a subspecialty core educator for endocrinology, and the Director of the Endocrine and Neuroendocrine Electives for MGH medical residents. He has also served on several national and international Committees in professional organizations, including the Endocrine Society, the American Association of Clinical Endocrinologists and the Pituitary Society.

Disclosures:

No relevant financial relationships.
Post-test, Panel Discussion, and Q&A
John D. Carmichael, MD(Co-Panelist)
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Nicholas A. Tritos, MD, DSc(Co-Panelist)
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Dr. Tritos is a staff neuroendocrinologist in the Neuroendocrine and Pituitary Tumor Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital (MGH) in Boston. He completed medical studies at The University of Athens (MD, DSc) and at Harvard Medical School (MMSc) where he now serves as Associate Professor of Medicine. Dr. Tritos completed his postgraduate medical training at Beth Israel Medical Center in Boston and received board certifications from the American Board of Internal Medicine in Endocrinology, Diabetes and Metabolism and Internal Medicine. Dr. Tritos’ main clinical and research interests include pituitary disease, growth hormone deficiency in adults and regulation of energy homeostasis. He mainly conducts clinical research focusing on pituitary tumors and growth hormone deficiency in adults. Dr. Tritos has served on the Curriculum Committee at Tufts University School of Medicine, currently serves as Chair of the Endocrine Fellowship Curriculum Committee, is a member of the Institutional Review Board and the Clinical Competency Committee at MGH, a subspecialty core educator for endocrinology, and the Director of the Endocrine and Neuroendocrine Electives for MGH medical residents. He has also served on several national and international Committees in professional organizations, including the Endocrine Society, the American Association of Clinical Endocrinologists and the Pituitary Society.

Disclosures:

No relevant financial relationships.
supported by:
This program is supported by an educational grant from Novo Nordisk, Inc., and Sandoz, Inc.
 

Learning Objectives:

  • Apply current guidelines, testing, and criteria in the individualized management of adult GHD
  • Recognize and effectively address barriers towards treatment adherence in pediatric patients transitioning to adult care
  • Analyze currently approved therapeutic regimens as well as emerging pharmaceuticals and delivery devices for adult patients with GHD.
Legislation & Regulations Affecting Endocrinologists: What You Need to Know About Medicare Physician Payment, Telehealth Expansion, and Drug Pricing
SEP 12
9:00 AM–9:50 AM EDT
Joshua J. Joseph, MD, MPH, FAHA(Panelist)
The Ohio State University Wexner Medical Division of Endocrinology, Diabetes and Metabolism, Columbus, OH, USA
Dr. Joshua Joseph is the Assistant Professor, Endocrinology, Diabetes and Metabolism, at The Ohio State University Wexner Medical Center. Dr. Joseph is an alumnus of Boston University School of Medicine, during which he spent two years at the National Institutes of Health in the Medical Research Scholars Program. In his diabetes and cardiovascular disease clinic, Dr. Joseph focuses on lifestyle behaviors and medical therapeutics through a team-based, patient-centered approach to living with diabetes that is tailored to provide patients with the necessary tools to successfully manage their diabetes.

Disclosures:

Associate Editor, Ethnicity & Health, American Heart Association Science Advisory and Coordinating Committee, Buckeye Health Plan Board Member
Erika Miller, JD(Panelist)
CRD Associates, Washington, DC, USA
Erika Miller is a consultant to the Endocrine Society where she brings her broad experience in government relations representing a range non- profit organizations ranging from medical specialty societies, coalitions, and patient advocacy organizations, including a number engaged on women’s health issues. Erika has expertise in the intricacies of Medicare policy and provides guidance on health policy, health care payment and quality.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Analyze new legislation and regulations concerning Medicare payment, telehealth expansion, and drug pricing
  • Understand the impact of the Medicare physician payment rule on their practice
  • Identify opportunities to share information with their patients about telehealth expansion and access to lower cost medications
  • Influence these policies and share their concerns by joining Endocrine Society campaigns
Thyroid Eye Disease: Early Diagnosis, Referral, and Treatment With TEPEZZA® (teprotumumab-trbw)
SEP 12
10:00 AM–10:35 AM EDT
Raymond S. Douglas, MD, PhD
Cedars-Sinai Medical Center, Los Angeles, CA, USA

Disclosures:

Consultant for Horizon Therapeutics and Immunovant.
sponsored by:
Horizon Therapeutics
 

Learning Objectives:

  • Describe the pathophysiology of Thyroid Eye Disease (TED)
  • Review the clinical signs and symptoms of TED to ensure an early diagnosis and referral to a TED specialist
  • Emphasize the importance of multidisciplinary TED management
  • Provide an overview of TEPEZZA efficacy, safety, and mechanism of action for the treatment of TED
Welcome and Introduction
SEP 12
10:55 AM–11:00 AM EDT
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
Master Clinician: Management of Aggressive Pituitary Tumors: When to Consider Alternative Nonsurgical Treatments
SEP 12
11:00 AM–11:45 AM EDT
Lisa B. Nachtigall, MD(Moderator)
Massachusetts General Hospital, Boston, MA, USA
Dr. Nachtigall is an Associate Professor of Medicine at Harvard Medical School, clinical director of the Neuroendocrine and Pituitary Tumor Clinical Center, director of International Programs for the Endocrine Division at Massachusetts General Hospital, and clerkship director for Neuroendocrine at Harvard Medical School. Dr. Nachtigall earned her medical degree from New York University (NYU) School of Medicine, completed her internship and residency in internal medicine at Bellevue Hospital Center/NYU school of Medicine, and a clinical fellowship in endocrinology and metabolism at Massachusetts General Hospital/Harvard Medical School. She has been published in many high impact journals, serves on the editorial board of Pituitary and has presented at many national and international medical conferences in the field of pituitary disorders.

Disclosures:

Advisory Board Member: Recordati, Strongbridge
Research Investigator: Chiasma
Anthony P. Heaney, MD, PhD(Panelist)
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
Edward R. Laws, MD(Panelist)
Brigham and Women's Hospital, Boston, MA, USA
Dr. Laws received his bachelor's degree from Princeton University with honors in Economics and Sociology in the Special Program in American Civilization, and then attended the Johns Hopkins University School of Medicine in Baltimore, Maryland. He did his surgical internship and neurosurgical residency at Johns Hopkins. After completing his residency, he joined the faculty at the Johns Hopkins Medical School. In 1972, he moved to the Mayo Clinic in Rochester, Minnesota where he became Professor of Neurosurgery and developed major interests in Pituitary and Brain tumor treatment and research.  In 1987, he became Professor and Chairman of the Department of Neurosurgery at the George Washington University in Washington, DC, and in 1992 joined the faculty of the University of Virginia as Professor of Neurosurgery and Professor of Medicine, developing a Multidisciplinary Pituitary Center there. Subsequently, he was Professor of Neurosurgery at Stanford University. In 2008, he established the Pituitary/Neuroendocrine Center at Brigham and Women's Hospital, where he currently is Professor of Neurosurgery at Harvard Medical School. During his surgical career he has operated upon more than 8,000 brain tumors, of which over 6,000 have been pituitary lesions. Dr. Laws has served as President of the World Federation of Neurosurgical Societies, President of the Congress of Neurological Surgeons, Editor of Neurosurgery, President of the American Association of Neurological Surgeons, and President of the Pituitary Society. He has been the fifth neurosurgeon to become President of the American College of Surgeons and was elected to membership in the National Academy of Medicine. He remains actively involved in Brain and Pituitary tumor research and surgery.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain what the current concept of an "aggressive" pituitary tumor is
  • Discuss the role of a multidisciplinary approach to management of this entity
  • Identify up-to-date therapeutic options for these tumors.
Meet the Professor: Thyroid on the Internet: Myths and Misperceptions
SEP 12
11:00 AM–11:45 AM EDT
Anne R. Cappola, MD, ScM
University of Pennsylvania, Philadelphia, PA, USA
Dr. Cappola is a Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism, Director of Clinical Research in the Department of Medicine, and Director of the CTSA-funded Center for Human Phenomic Science at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cappola directs an NIH-funded research program on the hormonal alterations that occur with aging and the clinical impact of these changes, with a focus on the clinical impact of subclinical thyroid dysfunction in older individuals. Dr. Cappola is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the Interurban Clinical Club and an Associate Editor for JAMA.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the types of thyroid information that patients find on the internet
  • Review scientific evidence that supports or refutes internet claims as well as areas for which there is no scientific evidence
  • Select a framework for discussing thyroid information found on the internet with patients.
The Year in Thyroid
SEP 12
11:00 AM–11:45 AM EDT
Anthony Hollenberg, MD
Weill Cornell Medicine, New York, NY, USA
Dr. Hollenberg is the Sanford I. Weill Chair of Medicine in the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and the Physician-in-Chief at New York-Presbyterian Hospital. Dr. Hollenberg received his M.D. from the University of Calgary in Canada in 1986. He completed his Internal Medicine residency in 1989 and was Chief Resident in Medicine from 1990 to 1991 at the Beth Israel Hospital. Dr. Hollenberg then completed a fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital in 1993 and was recruited back to Beth Israel to start his laboratory. From 2011 until his recruitment to Weill Cornell Medicine and New York-Presbyterian Hospital, Dr. Hollenberg was Chief of the Division of Endocrinology, Diabetes and Metabolism, at Beth Israel Deaconess Medical Center and Director of Clinical and Translational Research Training Programs at Harvard Catalyst and Harvard Medical School where he was also a Professor of Medicine. Dr. Hollenberg’s research focuses on the hormonal regulation of metabolism, with a particular emphasis on the role of thyroid hormone. His work has important ramifications for the regulation of body weight and metabolism. Additionally, his laboratory focuses on understanding thyroid gland development and the possibilities for regenerative medicine.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss important recent advances in the field of thyroid cancer in 2021
  • Evaluate the most important new evidence related to thyroid dysfunction
  • Describe new data regarding thyroid physiology.
6,000 + Transsphenoidal Operations: Lessons Learned
SEP 12
12:00 PM–12:45 PM EDT
Edward R. Laws, MD
Brigham and Women's Hospital, Boston, MA, USA
Dr. Laws received his bachelor's degree from Princeton University with honors in Economics and Sociology in the Special Program in American Civilization, and then attended the Johns Hopkins University School of Medicine in Baltimore, Maryland. He did his surgical internship and neurosurgical residency at Johns Hopkins. After completing his residency, he joined the faculty at the Johns Hopkins Medical School. In 1972, he moved to the Mayo Clinic in Rochester, Minnesota where he became Professor of Neurosurgery and developed major interests in Pituitary and Brain tumor treatment and research.  In 1987, he became Professor and Chairman of the Department of Neurosurgery at the George Washington University in Washington, DC, and in 1992 joined the faculty of the University of Virginia as Professor of Neurosurgery and Professor of Medicine, developing a Multidisciplinary Pituitary Center there. Subsequently, he was Professor of Neurosurgery at Stanford University. In 2008, he established the Pituitary/Neuroendocrine Center at Brigham and Women's Hospital, where he currently is Professor of Neurosurgery at Harvard Medical School. During his surgical career he has operated upon more than 8,000 brain tumors, of which over 6,000 have been pituitary lesions. Dr. Laws has served as President of the World Federation of Neurosurgical Societies, President of the Congress of Neurological Surgeons, Editor of Neurosurgery, President of the American Association of Neurological Surgeons, and President of the Pituitary Society. He has been the fifth neurosurgeon to become President of the American College of Surgeons and was elected to membership in the National Academy of Medicine. He remains actively involved in Brain and Pituitary tumor research and surgery.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain the objectives and technical aspects of surgery for pituitary tumors
  • Describe the pituitary tumor subtypes that are most likely to be aggressive
  • Discuss postoperative hyponatremia and its consequences
Meet the Professor: Management of Hyperthyroidism in Pregnancy
SEP 12
12:00 PM–12:45 PM EDT
Susan J. Mandel, MD, MPH
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Recognize gestational changes in thyroid hormone physiology
  • Apply evidence-based recommendations for the treatment of maternal hyperthyroidism
  • Describe testing for potential fetal and neonatal thyrotoxicosis.
Thyroid Cancer Overdiagnosis
SEP 12
12:00 PM–12:45 PM EDT
Julie Ann Sosa, MD, MA
University of California, San Francisco, San Francisco, CA, USA
Dr. Sosa is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is an NIH- and FDA-funded investigator and author of more than 340 peer-reviewed publications and 80 book chapters and reviews, all largely focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. She has authored or edited 7 books. Dr Sosa is Treasurer of the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines. She is the Editor-in-Chief of the World Journal of Surgery. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton, MA at Oxford, and MD at Johns Hopkins, where she completed the Halsted residency and a fellowship.

Disclosures:

Member, Data Monitoring Committee, Medullary Thyroid Cancer Consortium Registry: GlaxoSmithKline, Novo Nordisk, Astra Zeneca, Eli Lilly
Institutional Research Funding: Exelixis and Eli Lilly
 

Learning Objectives:

  • Describe the evolving epidemiology of thyroid cancer in the U.S
  • Summarize the different interpretations of the data
  • Evaluate the evidence supporting different explanations.
Meet the Professor: Challenges in the Management of Cushing's Disease
SEP 12
1:00 PM–1:45 PM EDT
Anthony P. Heaney, MD, PhD
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
 

Learning Objectives:

  • Describe the spectrum of Cushing’s disease and its variable presentation
  • Outline the expanding therapeutic options in Cushing’s disease
  • Discuss the remaining unmet medical need and future goals.
Meet the Professor: Current Trends in Treatment of Hypopituitarism
SEP 12
1:00 PM–1:45 PM EDT
Lisa B. Nachtigall, MD
Massachusetts General Hospital, Boston, MA, USA
Dr. Nachtigall is an Associate Professor of Medicine at Harvard Medical School, clinical director of the Neuroendocrine and Pituitary Tumor Clinical Center, director of International Programs for the Endocrine Division at Massachusetts General Hospital, and clerkship director for Neuroendocrine at Harvard Medical School. Dr. Nachtigall earned her medical degree from New York University (NYU) School of Medicine, completed her internship and residency in internal medicine at Bellevue Hospital Center/NYU school of Medicine, and a clinical fellowship in endocrinology and metabolism at Massachusetts General Hospital/Harvard Medical School. She has been published in many high impact journals, serves on the editorial board of Pituitary and has presented at many national and international medical conferences in the field of pituitary disorders.

Disclosures:

Advisory Board Member: Recordati, Strongbridge
Research Investigator: Chiasma
 

Learning Objectives:

  • Recognize the clinical presentation of hypopituitarism
  • List the biochemical tests used to diagnose hypopituitarism
  • Explain the current management of hypopituitarism.
Thyroid Tumor Board
SEP 12
1:00 PM–1:45 PM EDT
Anne R. Cappola, MD, ScM(Moderator)
University of Pennsylvania, Philadelphia, PA, USA
Dr. Cappola is a Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism, Director of Clinical Research in the Department of Medicine, and Director of the CTSA-funded Center for Human Phenomic Science at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cappola directs an NIH-funded research program on the hormonal alterations that occur with aging and the clinical impact of these changes, with a focus on the clinical impact of subclinical thyroid dysfunction in older individuals. Dr. Cappola is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the Interurban Clinical Club and an Associate Editor for JAMA.

Disclosures:

No relevant financial relationships.
Susan J. Mandel, MD, MPH(Panelist)
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
Julie Ann Sosa, MD, MA, FACS(Panelist)
University of California, San Francisco, San Francisco, CA, USA
Dr. Sosa is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is an NIH- and FDA-funded investigator and author of more than 340 peer-reviewed publications and 80 book chapters and reviews, all largely focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. She has authored or edited 7 books. Dr Sosa is Treasurer of the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines. She is the Editor-in-Chief of the World Journal of Surgery. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton, MA at Oxford, and MD at Johns Hopkins, where she completed the Halsted residency and a fellowship.

Disclosures:

Member, Data Monitoring Committee, Medullary Thyroid Cancer Consortium Registry: GlaxoSmithKline, Novo Nordisk, Astra Zeneca, Eli Lilly
Institutional Research Funding: Exelixis and Eli Lilly
 

Learning Objectives:

  • Apply practice guideline recommendations to the management of differentiated thyroid cancer
  • Discuss the evidence that serves as the underpinning to those guidelines
  • Explain the controversies that might exist around management options.
Meet the Professor: The Thyroid and Body Weight
SEP 12
2:00 PM–2:45 PM EDT
Anthony Hollenberg, MD
Weill Cornell Medicine, New York, NY, USA
Dr. Hollenberg is the Sanford I. Weill Chair of Medicine in the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and the Physician-in-Chief at New York-Presbyterian Hospital. Dr. Hollenberg received his M.D. from the University of Calgary in Canada in 1986. He completed his Internal Medicine residency in 1989 and was Chief Resident in Medicine from 1990 to 1991 at the Beth Israel Hospital. Dr. Hollenberg then completed a fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital in 1993 and was recruited back to Beth Israel to start his laboratory. From 2011 until his recruitment to Weill Cornell Medicine and New York-Presbyterian Hospital, Dr. Hollenberg was Chief of the Division of Endocrinology, Diabetes and Metabolism, at Beth Israel Deaconess Medical Center and Director of Clinical and Translational Research Training Programs at Harvard Catalyst and Harvard Medical School where he was also a Professor of Medicine. Dr. Hollenberg’s research focuses on the hormonal regulation of metabolism, with a particular emphasis on the role of thyroid hormone. His work has important ramifications for the regulation of body weight and metabolism. Additionally, his laboratory focuses on understanding thyroid gland development and the possibilities for regenerative medicine.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain how thyroid hormone influences human physiology
  • Describe the metabolic effects of thyroid hormone
  • Identify novel mechanisms by which thyroid hormones may regulate body weight and metabolic disease.
Update on the Management of Thyroid Nodules
SEP 12
2:00 PM–2:45 PM EDT
Susan J. Mandel, MD, MPH
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Apply evidence-based evaluation for patients with thyroid nodules
  • Discuss the association of sonographic imaging with cancer risk and its application to FNA decision making
  • Assess the Bethesda cytology classification for reporting thyroid nodule FNA results and the indications for molecular testing.
Year in Clinical Pituitary
SEP 12
2:00 PM–2:45 PM EDT
Anthony P. Heaney, MD, PhD
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
 

Learning Objectives:

  • Discuss the highlights in translational and clinical pituitary research in the prior year
  • Summarize and provide a critical appraisal of high impact studies in the Neuroendocrine/Pituitary field published in 2020-2021
  • Describe the practical clinical application of the published findings.

Previous:

Welcome and Introduction
Not Currently Available
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
The Endocrinologist's Approach to Male Infertility
Not Currently Available
Arthi Thirumalai, MBBS
University of Washington, Seattle, WA, USA
Dr. Thirumalai is a board-certified physician at the Endocrine and Diabetes Care Center at UWMC-Roosevelt and the Atherosclerosis/Lipid Clinic at Harborview and a UW assistant professor of Medicine and Metabolism, Endocrinology and Nutrition. Dr. Thirumalai sees a wide array of patients with general endocrine problems and diabetes. She believes the only way to succeed in helping patients with these issues is to listen to their primary concerns and see how every aspect of their lives influences their medical outcomes. Dr. Thriumalai earned her M.D. at Lady Hardinge Medical Center in New Delhi, India. She is board certified in both Internal Medicine and Endocrinology/Diabetes/Metabolism and is a member of the Endocrine Society. Dr. Thirumalai’s clinical and research interests include general endocrinology including thyroid, parathyroid, adrenal, pituitary and bone disorders, diabetes, Inpatient hyperglycemia management, male reproductive physiology and male contraception.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain the different causes of male infertility
  • Identify when to do an evaluation for endocrinologic causes of male infertility
  • Interpret the diagnostic tests of male reproductive function
  • Outline a treatment algorithm for endocrine causes of male infertility.
Master Clinician: Clinical Challenges in Secondary Osteoporosis
Not Currently Available
Ann E. Kearns, MD, PhD(Moderator)
Mayo Clinic, Rochester, MN, USA
Dr. Kearns obtained her internal medicine training at the University of Chicago Hospitals, and her Endocrinology training at Massachusetts General Hospital. She joined the Mayo Clinic in Rochester, MN in 1998. She is currently the Chair of Quality and Safety in the Division of Endocrinology. Dr. Kearns has expertise in osteoporosis, calcium disorders, and metabolic bone disease. She is also involved in Quality Improvement especially in osteoporosis evaluation and management after a fracture.

Disclosures:

No relevant financial relationships.
Suzanne M. Jan de Beur, MD(Panelist)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
Benjamin Leder, MD(Panelist)
Massachusetts General Hospital, Boston, MA, USA
Dr. Leder received his medical degree from Harvard Medical School and completed his Internal Medicine Residency and Endocrine Fellowship at Massachusetts General Hospital, where he has remained ever since. His current position is Professor of Medicine at Harvard Medical School. Over the past two decades, Dr. Leder has been both an active clinician (serving as the Director of Endocrine Associates, a 16-physician practice focusing on metabolic bone disease) and clinical investigator. His NIH-funded research focuses on developing novel therapeutic approaches to the management of postmenopausal osteoporosis and other metabolic bone diseases.

Disclosures:

Advisory Board Member: Radius
Grant Recipient: Amgen
 

Learning Objectives:

  • Develop a strategy to evaluate men for secondary causes of osteoporosis
  • Utilize genetic testing in select patients to evaluate secondary causes of osteoporosis
  • Optimize nutritional factors contributing to secondary osteoporosis.
What's New in Lipid Lowering Therapies?
Not Currently Available
Michael J. Blaha, MD, MPH
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Blaha (Professor of Cardiology and Epidemiology) is the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Dr. Blaha has published over 500 scientific articles, with a focus on appropriate use of tests and new therapies in the prevention of atherosclerotic cardiovascular disease. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 20 trainees, many of which have gone on to hold prominent academic appointments. Clinically, he practices as a preventive cardiologist and in the interpretation of cardiac CT. His clinic specializes in patients with advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk.

Disclosures:

Advisory Board Member: Bayer, Kaleido, Roche
Consultant: Kowa
Grant Recipient: 89Bio, Amgen, Novo Nordisk
Research Investigator: Novartis
 

Learning Objectives:

  • Discuss the mechanism of action of new lipid-lowering pharmacotherapies
  • Review the indications for newer available lipid-lowering therapies, and discuss strategies for their use in primary and secondary prevention
  • Describe the pipeline of potential future lipid-lowering therapies.
Endocrine Debate: Testosterone Therapy in Women: Never or Sometimes?
Not Currently Available
Kathryn A. Martin, MD(Moderator)
Massachusetts General Hospital, Boston, MA, USA
Dr. Martin is a faculty member and practicing clinician in the Reproductive Endocrine Unit at Massachusetts General Hospital. She has an active teaching role, including the training and supervision of junior faculty members and endocrine fellows. Her research interests have been in the area of female reproduction, in particular, the pathophysiology and management of isolated GnRH deficiency and functional hypothalamic amenorrhea. She has written and lectured extensively on the evaluation and management of menopausal women. Dr. Martin has had a number of leadership roles in the Endocrine Society; she has been chair of several committees including the Nominating Committee and the Clinical Practice Guidelines committee, and she is currently a member of the Board of Directors. Dr. Martin is also the Senior Deputy Editor for Endocrinology and Patient Education, as well as a member of the GRADE/EBM group at UpToDate, an online clinical reference for physicians.

Disclosures:

Employee: UpToDate/WoltersKluwer
Susan R. Davis, MBBS, FRACP, PhD(Panelist)
Monash University, Melbourne, VIC, Australia
Dr. Davis is an NHMRC Senior Principal Research Fellow, Director, Monash University Women’s Health Research Program, Consultant Endocrinologist and Head, Specialist Women’s Health Clinic, Alfred Hospital Melbourne and consultant at Cabrini Medical Centre. Her research has advanced the understanding of estrogen and testosterone action, deficiency and replacement in women. She is a past president of the Australasian Menopause Society and immediate past President of the International Menopause Society. She has over 420 peer-reviewed publications and in numerous awards. In 2021 Prof Davis was appointed an Officer of the Order of Australia distinguished service to medicine, to women's health as a clinical endocrinologist and researcher, and to medical education.

Disclosures:

Advisory Board Member: Mayne Pharmaceuticals, Theramex
Consultant: Lawley Pharm, Que Oncology
Speaker: BioFemme, Besins Healthcare
Margaret E. Wierman, MD(Panelist)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Wierman is a Professor of Medicine, Integrative Physiology at the University of Colorado School of Medicine. She directs the Pituitary and Adrenal Tumor Program. Dr. Wierman is a translational physician scientist whose research interest has been in reproductive endocrinology and sex hormone action, and more recently in the molecular mechanisms of pituitary tumors and adrenal cancer. She has led many committees in the Endocrine Society and is Past Clinical Scientist Vice President. She directs the Program to Advance Gender Equity in the Department of Medicine at the University of Colorado. Dr. Wierman has a long track record in mentoring and pipeline development of academic researchers. She received the Women in Endocrinology Mentor Award and the Endocrine Society Laureate Mentor Award from the Endocrine Society. Dr. Wierman is currently the Chair of the International Society of Endocrinology

Disclosures:

Research Investigator: Corcept, Novo Nordisk
 

Learning Objectives:

  • Describe the assessment for possible testosterone therapy in post-menopausal women
  • Describe the indications for androgen therapy in women
  • Describe the data about the risk of androgen therapy in women for hypoactive sexual desire disorder.
Meet the Professor: Calcium Conundrums
Not Currently Available
Ann E. Kearns, MD, PhD(Panelist)
Mayo Clinic, Rochester, MN, USA
Dr. Kearns obtained her internal medicine training at the University of Chicago Hospitals, and her Endocrinology training at Massachusetts General Hospital. She joined the Mayo Clinic in Rochester, MN in 1998. She is currently the Chair of Quality and Safety in the Division of Endocrinology. Dr. Kearns has expertise in osteoporosis, calcium disorders, and metabolic bone disease. She is also involved in Quality Improvement especially in osteoporosis evaluation and management after a fracture.

Disclosures:

No relevant financial relationships.
Suzanne M. Jan de Beur, MD(Panelist)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
 

Learning Objectives:

  • Describe pathophysiology of basic mineral metabolism
  • Recognize the clinical presentation of disorders of hypo and hypercalcemia
  • Discuss how to optimize regimens for hypocalcemia.
Meet the Professor: When is a Lipid Panel Not Enough?
Not Currently Available
Michael J. Blaha, MD, MPH
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Blaha (Professor of Cardiology and Epidemiology) is the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Dr. Blaha has published over 500 scientific articles, with a focus on appropriate use of tests and new therapies in the prevention of atherosclerotic cardiovascular disease. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 20 trainees, many of which have gone on to hold prominent academic appointments. Clinically, he practices as a preventive cardiologist and in the interpretation of cardiac CT. His clinic specializes in patients with advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk.

Disclosures:

Advisory Board Member: Bayer, Kaleido, Roche
Consultant: Kowa
Grant Recipient: 89Bio, Amgen, Novo Nordisk
Research Investigator: Novartis
 

Learning Objectives:

  • Describe the role of other markers of CVD risk such as lipoprotein(a), apoB and hsCRP
  • Review the guidelines for measuring and using Coronary Artery Calcium scores
  • Explain the role of lipid-lowering therapies in the setting of elevated non-traditional markers of CVD risk.
T Test: What is the Best Test?
Not Currently Available
Shehzad Basaria, MD
Brigham and Women's Hospital, Boston, MA, USA
Dr. Basaria is Professor of Medicine at Harvard Medical School/Brigham and Women's Hospital, and Associate Director of the Section of Men's Health, Aging and Metabolism. His clinical and research interests are in the field of Male Reproduction. His work focuses on cardiometabolic complications of androgen deprivation therapy in men with prostate cancer and the efficacy of testosterone replacement in men with opioid-induced androgen deficiency.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the criteria for the diagnosis of the male hypogonadism
  • Identify what laboratory tests should be used to diagnose male hypogonadism
  • Explain the controversy about the value of assessment of total testosterone versus free testosterone in the diagnosis of male hypogonadism.
  • Discuss how medical conditions and medications influence serum sex steroid concentrations.
Updates in Osteoporosis Treatment
Not Currently Available
Benjamin Leder, MD
Massachusetts General Hospital, Boston, MA, USA
Dr. Leder received his medical degree from Harvard Medical School and completed his Internal Medicine Residency and Endocrine Fellowship at Massachusetts General Hospital, where he has remained ever since. His current position is Professor of Medicine at Harvard Medical School. Over the past two decades, Dr. Leder has been both an active clinician (serving as the Director of Endocrine Associates, a 16-physician practice focusing on metabolic bone disease) and clinical investigator. His NIH-funded research focuses on developing novel therapeutic approaches to the management of postmenopausal osteoporosis and other metabolic bone diseases.

Disclosures:

Advisory Board Member: Radius
Grant Recipient: Amgen
 

Learning Objectives:

  • Recognize potential causes and contributors to the current crises in osteoporosis care
  • Assess the relative efficacy and limitations of anabolic and antiresorptive osteoporosis therapies
  • Summarize the relative efficacy of various sequential and combination approaches to osteoporosis management.
What the Endocrinologist Needs to Know About the Diagnosis and Management of Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
Not Currently Available
Kenneth Cusi, MD
University of Florida, Gainesville, FL, USA
Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville, and at the Veterans Administration Medical Center at Gainesville, FL (2011-present). He completed his medical training and residency in Buenos Aires, Argentina, and fellowship in endocrinology at Baylor College of Medicine, Houston, Texas. He worked after his training at the University of San Antonio Health Science Center, Texas (1992-2011) on the role of defects in insulin secretion/insulin resistance in the development of T2DM and later focused on the underlying mechanisms and new treatments for nonalcoholic fatty liver disease (NAFLD) in T2DM. Dr. Cusi has published over 200 original articles, editorials, reviews and book chapters in the fields of diabetes, obesity and liver disease. He has contributed to several guidelines in NAFLD. His basic and clinical research programs in diabetes and fatty liver disease include funding from the NIH and from industry examining new treatments for NASH. The University of Florida awarded him in 2015 two awards, the Exemplary Teacher Award and the Clinical Research Award for Outstanding Achievement, Research Discovery, and Productivity. In 2020, he received the American Association of Clinical Endocrinologists (AACE) Jack Baskin, MD, Endocrine Teaching Award.

Disclosures:

Advisory Board Member: Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal
Research Investigator: Echosens, Inventiva, Novo Nordisk, Poxel, Zydus
 

Learning Objectives:

  • Recognize the magnitude of the problem and the mechanisms leading to steatohepatitis in patients with obesity and type 2 diabetes mellitus
  • Compare the diagnostic tools available for NAFLD and hepatic fibrosis and select the best tools for your practice
  • Evaluate current treatment modalities for steatohepatitis, both as monotherapy and in combination, and for the management of associated comorbidities (obesity, insulin resistance, dyslipidemia, CVD).
Disorders of Phosphate
Not Currently Available
Suzanne M. Jan de Beur, MD
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Jan de Beur is an Associate Professor of Medicine at The Johns Hopkins University School of Medicine and the Director of the Clinical Research Unit Network of the Johns Hopkins Institute for Clinical and Translational Research. She received her B.A. and her M.D. degree from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. As a Physician-Scientist and a practicing Endocrinologist, her clinical and research work focus on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. She is an internationally recognized expert in metabolic bone disease and is frequently invited to speak internationally on skeletal health. Dr. Jan de Beur is leader in several professional organizations and is currently President of the American Society of Bone and Mineral Research.

Disclosures:

Advisory Board Member: Inozyme, Kyowa Kirin, Ultragenyx
Consultant: Inozyme, Kyowa Kirin, Ultragenyx
Research Investigator: Mereo, Ultragenyx
 

Learning Objectives:

  • Discuss hormonal regulation phosphate homeostasis
  • Explain the differential diagnosis of hypophosphatemia and hyperphosphatemia based on clinical and biochemical characteristic
  • Describe new treatment options for some forms of FGF23 mediated hypophosphatemia.
Master Clinician: Alopecia in Women: The Endocrinologist's Approach
Not Currently Available
Margaret E. Wierman, MD(Moderator)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Wierman is a Professor of Medicine, Integrative Physiology at the University of Colorado School of Medicine. She directs the Pituitary and Adrenal Tumor Program. Dr. Wierman is a translational physician scientist whose research interest has been in reproductive endocrinology and sex hormone action, and more recently in the molecular mechanisms of pituitary tumors and adrenal cancer. She has led many committees in the Endocrine Society and is Past Clinical Scientist Vice President. She directs the Program to Advance Gender Equity in the Department of Medicine at the University of Colorado. Dr. Wierman has a long track record in mentoring and pipeline development of academic researchers. She received the Women in Endocrinology Mentor Award and the Endocrine Society Laureate Mentor Award from the Endocrine Society. Dr. Wierman is currently the Chair of the International Society of Endocrinology

Disclosures:

Research Investigator: Corcept, Novo Nordisk
Andrea Kalus, MD(Panelist)
University of Washington, Seattle, WA, USA
Dr. Kalus, co-directs the Rheumatology-Dermatology Clinic at the UW Roosevelt Clinic. Her clinical practice focuses on autoimmune diseases, complex medical dermatology and phototherapy. Dr. Kalus earned her M.D. at the University of Washington. She completed residency training in both internal medicine and dermatology. Dr. Kalus partners with multidisciplinary research teams to study lupus, dermatomyositis and skin manifestations of systemic disease.

Disclosures:

Grant Recipient: Janssen, Lilly
Kathryn A. Martin, MD(Panelist)
Massachusetts General Hospital, Boston, MA, USA
Dr. Martin is a faculty member and practicing clinician in the Reproductive Endocrine Unit at Massachusetts General Hospital. She has an active teaching role, including the training and supervision of junior faculty members and endocrine fellows. Her research interests have been in the area of female reproduction, in particular, the pathophysiology and management of isolated GnRH deficiency and functional hypothalamic amenorrhea. She has written and lectured extensively on the evaluation and management of menopausal women. Dr. Martin has had a number of leadership roles in the Endocrine Society; she has been chair of several committees including the Nominating Committee and the Clinical Practice Guidelines committee, and she is currently a member of the Board of Directors. Dr. Martin is also the Senior Deputy Editor for Endocrinology and Patient Education, as well as a member of the GRADE/EBM group at UpToDate, an online clinical reference for physicians.

Disclosures:

Employee: UpToDate/WoltersKluwer
 

Learning Objectives:

  • Describe the pathophysiology of common causes of alopecia in women
  • Diagnose female pattern hair loss.
  • Recognize the clinical features and diagnostic approach to scarring and non-scarring hair loss
  • Identify the diagnostic evaluation for endocrinopathies in women who have alopecia.
  • Discuss the treatment options for common causes of alopecia in women.
Meet the Professor: Overcoming Barriers to Obesity Therapy, a Case-Based Approach
Not Currently Available
Ania M. Jastreboff, MD, PhD
Yale School of Medicine, New Haven, CT, USA
Dr. Jastreboff is an Associate Professor of Internal Medicine & Pediatrics (Endocrinology & Pediatric Endocrinology) at Yale University School of Medicine, Director of Weight Management and Obesity Prevention at the Yale Stress Center, and co-Director of the Yale Center for Weight Management. After completing a Med/Peds Residency, Dr. Jastreboff completed a dual fellowship in both Adult Endocrinology and Pediatric Endocrinology during which she also completed a PhD in the neurobiology of obesity, becoming board certified in Obesity Medicine, Adult Endocrinology, and Pediatric Endocrinology. Dr. Jastreboff is a clinically active physician-scientist nationally and internationally recognized for helping to develop the 2016 Clinical Practice Guidelines for The Comprehensive Care of Patients with Obesity (AACE/ACE), educating the next generation of Obesity Medicine physicians by teaching annually at the Harvard Blackburn Treating Obesity course, the Columbia/Cornell Obesity course, selected international courses, and conducting cutting-edge clinical translational obesity research. Her research includes both large, multi-center clinical outcomes trials using anti-obesity medication as well as neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and the mechanisms of anti-obesity medications. Dr. Jastreboff's research is supported by NIH/NIDDK (K23, R01s), American Diabetes Association (ADA), and industry funded multi-center clinical trials. Nationally, she serves as the vice-Chair of the Clinical Care Committee of The Obesity Society (TOS) and has been selected to serve as a Director on the American Board of Obesity Medicine (ABOM). Clinically, Dr. Jastreboff specializes in sophisticated use of anti-obesity medication combinations to help patients reach their weight and health goals.

Disclosures:

Consultant: Boehringer Ingelheim, Eli Lilly, Novo Nordisk
Grant Recipient: American Diabetes Association, NIH/NIDDK
Site-PI for Multi-Center Trial: Eli Lilly, Novo Nordisk
 

Learning Objectives:

  • Identify and overcome barriers to treating obesity
  • Become familiar with available anti-obesity medications and key concepts in their use for treating patients with obesity
  • Understand the importance of comprehensive care for individuals with obesity.
Ancillary Symposium: Challenges in Diagnosing and Managing Patients with Fibrodysplasia Ossificans Progressiva
Not Currently Available
Welcome and Introduction
Kelly L. Wentworth, MD
University of California, San Francisco, San Francisco, CA, USA
Dr. Wentworth is an Assistant Professor in the Department of Medicine, Division of Endocrinology at Zuckerberg San Francisco General Hospital, University of California, San Francisco. She has a clinical and research interest in metabolic bone disorders, with a specific focus on fibrous dysplasia/McCune-Albright Syndrome and fibrodysplasia ossificans progressiva (FOP).  She is currently funded by an NIH/NIDCR K08 career development grant.

Disclosures:

Research Investigator: Ipsen pharmaceuticals
Clinical Presentation and Treatment Options for Patients with FOP
Mona Al Mukaddam, MD, MS(Panelist)
Penn Medicine University City, Philadelphia, PA, USA
Dr. Al Mukaddam is an adult endocrinologist in the Division of Endocrinology, Diabetes and Metabolism at the Pennsylvania and Director of the Penn Bone Center. Dr. Al Mukaddam received her Bachelor of Science and Medical Degrees from American University in Beirut, Lebanon. She completed her internship and residency in internal medicine at the University of Iowa, a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Penn, and received a Master of Science Degree in translational medicine and therapeutics at the University of Pennsylvania. Dr. Al Mukaddam is board certified in endocrinology, diabetes and metabolism. She is the principal investigator on ongoing clinical trials in FOP at the Center for Research in FOP & Related Disorders at Penn and is a founding member of the International Clinical Council on FOP (ICC).

Disclosures:

Research Investigator: Clementia/Ipsen Pharmaceuticals, Regeneron
Elisabeth M.W. Eekhoff, MD, PhD(Panelist)
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Basic and Translational Science Advancements in FOP
Benjamin Levi, MD
UT Southwestern Medical Center, Boston, MA, USA
Dr. Levi holds the Dr. Lee Hudson-Robert R. Penn Chair in Surgery and Plastic and Reconstructive Surgery and serves as Chief of the Division of Burn, Trauma, Acute and Critical Care Surgery. He specializes in acute and reconstructive burn surgery and scar reconstructive surgery. Certified by the American Board of Plastic Surgery and the American Board of Surgery, Dr. Levi joined the UT Southwestern faculty in 2020. Previously, he was Director of the Burn/Wound and Regenerative Medicine Laboratory and Associate Director of Burn Surgery Service at the University of Michigan. Dr. Levi’s research interests, which are funded by the National Institutes of Health, the American College of Surgeons, and the Department of Defense, include stem cell biology, heterotopic ossification, muscle fibrosis, tissue regeneration, wound healing and repair, and burn reconstruction outcomes.

Disclosures:

No relevant financial relationships.
Future Management Options for Patients with FOP
Elisabeth M.W. Eekhoff, MD, PhD
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Post-test, Panel Discussion, and Q&A
Kelly L. Wentworth, MD(Moderator)
University of California, San Francisco, San Francisco, CA, USA
Dr. Wentworth is an Assistant Professor in the Department of Medicine, Division of Endocrinology at Zuckerberg San Francisco General Hospital, University of California, San Francisco. She has a clinical and research interest in metabolic bone disorders, with a specific focus on fibrous dysplasia/McCune-Albright Syndrome and fibrodysplasia ossificans progressiva (FOP).  She is currently funded by an NIH/NIDCR K08 career development grant.

Disclosures:

Research Investigator: Ipsen pharmaceuticals
Mona Al Mukaddam, MD, MS(Panelist)
Penn Medicine University City, Philadelphia, PA, USA
Dr. Al Mukaddam is an adult endocrinologist in the Division of Endocrinology, Diabetes and Metabolism at the Pennsylvania and Director of the Penn Bone Center. Dr. Al Mukaddam received her Bachelor of Science and Medical Degrees from American University in Beirut, Lebanon. She completed her internship and residency in internal medicine at the University of Iowa, a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Penn, and received a Master of Science Degree in translational medicine and therapeutics at the University of Pennsylvania. Dr. Al Mukaddam is board certified in endocrinology, diabetes and metabolism. She is the principal investigator on ongoing clinical trials in FOP at the Center for Research in FOP & Related Disorders at Penn and is a founding member of the International Clinical Council on FOP (ICC).

Disclosures:

Research Investigator: Clementia/Ipsen Pharmaceuticals, Regeneron
Elisabeth M.W. Eekhoff, MD, PhD(Panelist)
Amsterdam UMC location Vumc, Amsterdam, Netherlands
Dr. Eekhoff is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002. She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004). Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)). Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.

Disclosures:

Grants/Funding: IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen
Benjamin Levi, MD(Panelist)
UT Southwestern Medical Center, Boston, MA, USA
Dr. Levi holds the Dr. Lee Hudson-Robert R. Penn Chair in Surgery and Plastic and Reconstructive Surgery and serves as Chief of the Division of Burn, Trauma, Acute and Critical Care Surgery. He specializes in acute and reconstructive burn surgery and scar reconstructive surgery. Certified by the American Board of Plastic Surgery and the American Board of Surgery, Dr. Levi joined the UT Southwestern faculty in 2020. Previously, he was Director of the Burn/Wound and Regenerative Medicine Laboratory and Associate Director of Burn Surgery Service at the University of Michigan. Dr. Levi’s research interests, which are funded by the National Institutes of Health, the American College of Surgeons, and the Department of Defense, include stem cell biology, heterotopic ossification, muscle fibrosis, tissue regeneration, wound healing and repair, and burn reconstruction outcomes.

Disclosures:

No relevant financial relationships.
supported by:
This program is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.
 

Learning Objectives:

  • Analyze clinical presentations of FOP in individuals
  • Review the importance of early diagnosis and management of FOP
  • Describe the best practices in the diagnosis and management of patients with FOP
Welcome and Introduction
Not Currently Available
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
Automated Insulin Delivery in the Management of T1DM
Not Currently Available
Anne L. Peters, MD
University of Southern California, Los Angeles, CA, USA
Dr. Peters is a Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes programs at Cedars-Sinai and UCLA. Her research has focused on testing new approaches for diagnosing and treating diabetes and developing systems of care to improve outcomes in diabetic populations. She has published over 200 articles, reviews, and abstracts and three books on diabetes. She has been an investigator on over 40 research studies and has spoken at over 400 programs throughout the US as well as internationally. She has served on many committees for the ADA and other organizations. Currently she is the chair of the Endocrine Society Committee on Diabetes Devices and is on the EASD/ADA Technology Safety Committee. Additionally she is a member of the JDRF Panel on Management of Exercise in Type 1 Diabetes. She is a member of the ABIM Endocrinology Subspecialty Board. She consults for many entities, including the FDA, Optum Rx and CVS/Caremark to help guide the development and use of treatments for diabetes.

Disclosures:

Advisory Board Member: Eli Lilly, Novo Nordisk, Zealand
Research Investigator: Abbot Diabetes Care, Dexcom, Insulet
Stock Options: Omada Health, Teladoc
 

Learning Objectives:

  • Review the strengths of hybrid closed loop technology
  • Summarize the weaknesses of hybrid closed loop technology
  • Identify patients who would benefit most from closed-loop technologies and those for whom it may not be appropriate.
Master Clinician: CKD and Diabetes: Management of Diabetes in Patients with Progressive CKD
Not Currently Available
Rita R. Kalyani, MD, MHS(Moderator)
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Kalyani is an Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at Johns Hopkins University School of Medicine. She graduated with an undergraduate degree from Harvard College and completed her medical degree, residency, and fellowship at Johns Hopkins. Dr. Kalyani is an active clinician and sees patients regularly in the Johns Hopkins Comprehensive Diabetes Center. She directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program. A recipient of NIH grant funding, Dr. Kalyani's research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases. She has served on the editorial boards of several diabetes research journals and has authored more than 125 peer-reviewed publications. Dr. Kalyani is a past Chair of the American Diabetes Association’s Professional Practice Committee which is responsible for the annual clinical guidelines statement, “ADA Standards of Medical Care in Diabetes”. She is the Editor-in-Chief of the Johns Hopkins Patient Guide to Diabetes website. Dr. Kalyani currently serves on the Clinical Guidelines Committee for the Endocrine Society.

Disclosures:

No relevant financial relationships.
Silvio E. Inzucchi, MD(Panelist)
Yale School of Medicine, New Haven, CT, USA
Dr. Inzucchi is a Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center. He is well known as an author and lecturer in diabetes management for more than two decades. He served as co-chair of the ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes and has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.

Disclosures:

Advisory Board Member: Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Lexicon, Merck, Novo Nordisk, VTV Therapeutics
Consultant: Abbott, Esperion, Merck, vTv Therapeutics
Speaker: AstraZeneca, Boehringer Ingelheim
Clinical Trial Publications Committee Member: Boehringer Ingelheim
Clinical Trial Executive Committee Member: AstraZeneca
Clinical Trial Steering Committee Member: Novo Nordisk
Robert C. Stanton, MD(Panelist)
Joslin Diabetes Center, Boston, MA, USA
Dr. Stanton is Chief of the Kidney and Hypertension Section at the Joslin Diabetes Center, a Principal Investigator (Section on Vascular Cell Biology), and an Associate Professor of Medicine at Harvard Medical School. Dr. Stanton has given many invited lectures throughout the world and written many original articles and reviews on clinical and basic science aspects of diabetic kidney disease. Dr. Stanton’s research is focused on the essential enzyme, glucose 6-phosphate dehydrogenase (G6PD). His lab has discovered that this enzyme (and associated pathway) is essential for cell survival and dysregulation of G6PD plays an important role in the pathogenesis of many diseases. He has received honorary professorships from other universities and a major lifetime-achievement teaching award for Sustained Excellence in Teaching from Harvard Medical School.

Disclosures:

Advisory Board Member: Bayer Pharmaceuticals
 

Learning Objectives:

  • Discuss the renoprotection of new antihyperglycemic agents
  • Describe safe use of antihyperglycemic medications in patients with kidney disease
  • Identify clinical trials demonstrating that specific antihyperglycemic drugs delay the progression of kidney disease.
Meet the Professor: Tips for Clinicians for Genetic Evaluations of Adrenal Disorders
Not Currently Available
Lauren Fishbein, MD, PhD
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Fishbein is an Associate Professor at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes. She earned an MD, PhD degree from the University of Florida, and completed Internal Medicine Residency at Harvard’s Beth Israel Deaconess Medical Center and Endocrinology Fellowship at the University of Pennsylvania. Her research and clinical interests are in neuroendocrine tumor genetics. Dr. Fishbein has a strong interest in personalized medicine including understanding the impact of germline predisposition genetics, as well as understanding neuroendocrine tumor development and metastatic disease. Dr. Fishbein is a member of the Endocrine Society’s Annual Meeting Steering Committee and previously served as co-chair of the Trainee and Career Development Core Committee.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify when to refer a patient with an adrenal tumor for clinical genetic testing
  • List genetic predisposition syndromes associated with adrenal tumor.
  • Describe how to screen patients with hereditary predisposition for pheochromocytoma/paraganglioma.
Health Disparities in Diabetes
Not Currently Available
Rocio I. Pereira, MD
Denver Health, Denver, CO, USA
Dr. Pereira is the Chief of Endocrinology at Denver Health, Associate Professor of Medicine at the University of Colorado, Division of Endocrinology, Metabolism, and Diabetes, and the Founder and Director of the Vuela for Health lifestyle intervention program for Latino immigrants. The primary focus of Dr. Pereira’s work is addressing health disparities in diabetes and obesity. Dr. Pereira has been a member of the Endocrine Society since 2001. She has served as Chair of the Minority Affairs Committee/Committee on Diversity and Inclusion (CODI), and contributed to a number of other Society efforts. Dr. Pereira is currently a member of the Board of Directors, Board representative to CODI, and the Program Director for the upcoming EXCEL- Excellence in Clinical Endocrinology and Leadership program.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Summarize the nature and extent of disparities in diabetes affecting national and global racial and ethnic minority communities
  • Recognize systemic racism as the fundamental underlying cause of health disparities
  • Apply knowledge of health equity best practices to identify actions to address health disparities.
Meet the Professor: Management of Adrenal Tumors in Pregnancy
Not Currently Available
William F. Young Jr., MD, MSc
Mayo Clinic, Rochester, MN, USA
Dr. Young is the Tyson Family Endocrinology Clinical Professor and Professor of Medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minnesota, USA. He is the recipient of multiple education awards and is a past president of the Endocrine Society and past chair of the Division of Endocrinology at Mayo Clinic. Dr. Young’s clinical research focuses on primary aldosteronism and pheochromocytoma. He has published more than 300 articles on endocrine hypertension and adrenal and pituitary disorders. He has delivered more than 650 presentations at national and international meetings and he has been an invited visiting professor for more than 150 medical institutions.

Disclosures:

Adrenal Safety Monitor for Progesterone Receptor Modulator Trial: Bayer
 

Learning Objectives:

  • Discuss treatment options for the woman with a catecholamine-secreting tumor diagnosed during pregnancy
  • Review the potential effects of pregnancy on underlying primary aldosteronism and impact on treatment decisions
  • Determine the most likely cause for Cushing syndrome during pregnancy to direct optimal management.
Meet the Professor: Pancreatogenic Diabetes
Not Currently Available
Rita R. Kalyani, MD, MHS
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Kalyani is an Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at Johns Hopkins University School of Medicine. She graduated with an undergraduate degree from Harvard College and completed her medical degree, residency, and fellowship at Johns Hopkins. Dr. Kalyani is an active clinician and sees patients regularly in the Johns Hopkins Comprehensive Diabetes Center. She directs the Diabetes Management Service for Johns Hopkins’ Total Pancreatectomy Islet Auto Transplant Program. A recipient of NIH grant funding, Dr. Kalyani's research focuses on diabetes and aging and investigates accelerated muscle loss, disability, and frailty in older adults with diabetes. Other research interests include sex differences in diabetes and heart disease and physical functioning in other endocrine and metabolic diseases. She has served on the editorial boards of several diabetes research journals and has authored more than 125 peer-reviewed publications. Dr. Kalyani is a past Chair of the American Diabetes Association’s Professional Practice Committee which is responsible for the annual clinical guidelines statement, “ADA Standards of Medical Care in Diabetes”. She is the Editor-in-Chief of the Johns Hopkins Patient Guide to Diabetes website. Dr. Kalyani currently serves on the Clinical Guidelines Committee for the Endocrine Society.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss the relationship of pancreatic disease to the development of diabetes
  • Describe the different etiologies for pancreatogenic diabetes
  • Outline unique considerations in diabetes management in pancreatogenic diabetes.
Important and Practice-Changing Publications in Diabetes, 2021
Not Currently Available
Silvio E. Inzucchi, MD
Yale School of Medicine, New Haven, CT, USA
Dr. Inzucchi is a Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center. He is well known as an author and lecturer in diabetes management for more than two decades. He served as co-chair of the ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes and has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.

Disclosures:

Advisory Board Member: Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Lexicon, Merck, Novo Nordisk, VTV Therapeutics
Consultant: Abbott, Esperion, Merck, vTv Therapeutics
Speaker: AstraZeneca, Boehringer Ingelheim
Clinical Trial Publications Committee Member: Boehringer Ingelheim
Clinical Trial Executive Committee Member: AstraZeneca
Clinical Trial Steering Committee Member: Novo Nordisk
 

Learning Objectives:

  • Summarize key findings from recent practice-changing publications in diabetes
  • Explain the context of recent important publications in diabetes
  • Outline potential implications of recent key publications in diabetes.
Master Clinician: Chromaffin Tumors Perspectives
Not Currently Available
Lauren Fishbein, MD, PhD(Moderator)
University of Colorado School of Medicine, Aurora, CO, USA
Dr. Fishbein is an Associate Professor at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes. She earned an MD, PhD degree from the University of Florida, and completed Internal Medicine Residency at Harvard’s Beth Israel Deaconess Medical Center and Endocrinology Fellowship at the University of Pennsylvania. Her research and clinical interests are in neuroendocrine tumor genetics. Dr. Fishbein has a strong interest in personalized medicine including understanding the impact of germline predisposition genetics, as well as understanding neuroendocrine tumor development and metastatic disease. Dr. Fishbein is a member of the Endocrine Society’s Annual Meeting Steering Committee and previously served as co-chair of the Trainee and Career Development Core Committee.

Disclosures:

No relevant financial relationships.
Anand Vaidya, MD, MMSc(Panelist)
Brigham and Women's Hospital, Boston, MA, USA
Dr. Vaidya is currently the Director of the Center for Adrenal Disorders at Brigham and Women’s Hospital and an Associate Professor at Harvard Medical School. He oversees the multi-disciplinary clinical care of patients with adrenal diseases and runs a translational research program. His research has helped characterize and redefine the severity spectrum of primary aldosteronism, the optimal approaches to treating primary aldosteronism, the genetics of pheochromocytoma-paraganglioma syndromes, and the systemic consequences of adrenal tumors and hypercortisolism. Dr. Vaidya is a dedicated educator; he is the director of the pre-clerkship endocrinology curriculum at HMS, he directs the interactive medical case series for the New England Journal of Medicine, and he regularly teaches clinical audiences about updates in adrenal diseases.

Disclosures:

Advisory Board Member: Mineralys
Consultant: Corcept, HRA Pharma
William F. Young Jr., MD, MSc(Panelist)
Mayo Clinic, Rochester, MN, USA
Dr. Young is the Tyson Family Endocrinology Clinical Professor and Professor of Medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minnesota, USA. He is the recipient of multiple education awards and is a past president of the Endocrine Society and past chair of the Division of Endocrinology at Mayo Clinic. Dr. Young’s clinical research focuses on primary aldosteronism and pheochromocytoma. He has published more than 300 articles on endocrine hypertension and adrenal and pituitary disorders. He has delivered more than 650 presentations at national and international meetings and he has been an invited visiting professor for more than 150 medical institutions.

Disclosures:

Adrenal Safety Monitor for Progesterone Receptor Modulator Trial: Bayer
 

Learning Objectives:

  • Describe how to do work up a patient with elevated catecholamines/metanephrines
  • Describe pitfalls of imaging and biochemical studies in the diagnosis of pheochromocytoma/paraganglioma
  • Select which imaging study is best for identifying pheochromocytoma/paraganglioma.
Utility of Adrenal Androgens in Clinical Practice
Not Currently Available
Adina F. Turcu, MD, MS
University of Michigan, Ann Arbor, MI, USA
Dr. Turcu is an Assistant Professor of Internal Medicine at University of Michigan, Ann Arbor. Dr. Turcu completed her Endocrinology fellowship at Mayo Clinic, Rochester, MN, and subsequently pursued a postdoctoral fellowship with focus on adrenal pathophysiology and steroid biology at the University of Michigan. Dr. Turcu’s research focuses on primary aldosteronism, congenital adrenal hyperplasia, Cushing syndrome, and adrenal androgenesis across ages. She has expertise in mass spectrometry and has a particular interest in identifying novel biomarkers with clinical relevance in adrenal disorders. Dr. Turcu’s research is currently supported by the NIH and by a Doris Duke Foundation Clinical Scientist Development Award. Dr. Turcu is the recipient of numerous prestigious awards, such as the Mayo Clinic Randall G. Sprague Award for outstanding clinical, investigative, and academic achievement in Endocrinology; the Women in Endocrinology Young Investigator Award; the Endocrine Society Early Investigators Award; and the ASCI's 2020 Young Physician-Scientist Awards.

Disclosures:

Advisory Board Member: CinCor
Consultant: Chiasma, Crinetics, PhaseBio, Poxel
 

Learning Objectives:

  • Discuss physiological sources of androgens, with emphasis on adrenal androgens
  • Identify the clinical utility of adrenal androgens in the diagnosis and management of disorders of androgens excess (Congenital adrenal hyperplasia, PCOS, Premature adrenarche)
  • Identify the clinical utility of adrenal androgens in assessing the hypothalamic-pituitary-adrenal axis (adrenal insufficiency and autonomous hypercortisolism).
Meet the Professor: Facing the Challenges of Severe Insulin Resistance
Not Currently Available
Anastassia Amaro, MD
University of Pennsylvania, Philadelphia, PA, USA
Dr. Amaro is an Associate Professor of Clinical Medicine in the Division of Endocrinology and Metabolism at the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Amaro, a graduate from Sechenov Moscow Medical Academy in Moscow, Russia, completed her residency in Internal Medicine at Lutheran General Hospital in Chicago, Illinois. Her fellowship training in Endocrinology and Metabolism was at Washington University and at the Barnes-Jewish Hospital in St. Louis, Missouri. Double-boarded in Endocrinology and Obesity Medicine, Dr. Amaro established Penn Metabolic Medicine (PMM) center and has been serving as the Medical Director of PMM since 2015. Penn Metabolic Medicine is a unique translational clinic dedicated to clinical care and research in subjects with obesity and abnormalities of carbohydrate metabolism. Dr. Amaro serves as an investigator on several clinical trials in obesity and diabetes.

Disclosures:

Advisory Board Member: Novo Nordisk
Research Investigator: Fractyl Laboratories, Inc.
 

Learning Objectives:

  • Summarize current medical knowledge of mechanisms of insulin resistance at various tissue levels
  • Discuss the therapeutic challenges of severe insulin resistance
  • Identify clinical strategies for maintaining glycemic control in severely insulin resistant patients.
Prevention and Management of Hypoglycemia
Not Currently Available
Kasia J. Lipska, MD, MHS
Yale School of Medicine, New Haven, CT, USA
Dr. Lipska is an Associate Professor of Medicine (Endocrinology) at the Yale School of Medicine and a Clinical Investigator at the Yale-New Haven Hospital Center for Outcomes Research and Evaluation (CORE). She received her medical degree from Harvard Medical School, completed internal medicine residency at the Brigham and Women’s Hospital, and her endocrine training at the Yale School of Medicine, where she also received a Masters degree in Health Science through the Robert Wood Johnson Clinical Scholars Program. Currently, she cares for patients at the Yale Diabetes Center, directs an NIH-funded research program focused on improving the safety and effectiveness of treatment of type 2 diabetes mellitus, and mentors students, trainees, and early stage faculty in diabetes outcomes research.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Identify risk factors for hypoglycemia
  • Describe strategies to reduce the risk of hypoglycemia
  • Outline the available treatments for hypoglycemia including newer formulations of glucagon.
Primary Aldosteronism: Once a Zebra, Now a Horse
Not Currently Available
Anand Vaidya, MD, MMSc
Brigham and Women's Hospital, Boston, MA, USA
Dr. Vaidya is currently the Director of the Center for Adrenal Disorders at Brigham and Women’s Hospital and an Associate Professor at Harvard Medical School. He oversees the multi-disciplinary clinical care of patients with adrenal diseases and runs a translational research program. His research has helped characterize and redefine the severity spectrum of primary aldosteronism, the optimal approaches to treating primary aldosteronism, the genetics of pheochromocytoma-paraganglioma syndromes, and the systemic consequences of adrenal tumors and hypercortisolism. Dr. Vaidya is a dedicated educator; he is the director of the pre-clerkship endocrinology curriculum at HMS, he directs the interactive medical case series for the New England Journal of Medicine, and he regularly teaches clinical audiences about updates in adrenal diseases.

Disclosures:

Advisory Board Member: Mineralys
Consultant: Corcept, HRA Pharma
 

Learning Objectives:

  • Identify primary aldosteronism as a highly prevalent and unrecognized syndrome that manifests across a continuum of severity
  • Describe how to recalibrate diagnostic interpretations to maximize diagnosis and treatment
  • Recognize how primary aldosteronism syndrome contributes to the pathogenesis of a large proportion of “idiopathic” hypertension and cardiovascular disease.
Ancillary Symposium: New Heights in Growth Hormone Deficiency: Advancements in Adult Patient Care
Not Currently Available
Welcome and Introduction
John D. Carmichael, MD
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Unique Diagnostic Challenges in Adult GHD
John D. Carmichael, MD
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Current, New, and Emerging GHD Therapeutic Options
Nicholas A. Tritos, MD, DSc
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Dr. Tritos is a staff neuroendocrinologist in the Neuroendocrine and Pituitary Tumor Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital (MGH) in Boston. He completed medical studies at The University of Athens (MD, DSc) and at Harvard Medical School (MMSc) where he now serves as Associate Professor of Medicine. Dr. Tritos completed his postgraduate medical training at Beth Israel Medical Center in Boston and received board certifications from the American Board of Internal Medicine in Endocrinology, Diabetes and Metabolism and Internal Medicine. Dr. Tritos’ main clinical and research interests include pituitary disease, growth hormone deficiency in adults and regulation of energy homeostasis. He mainly conducts clinical research focusing on pituitary tumors and growth hormone deficiency in adults. Dr. Tritos has served on the Curriculum Committee at Tufts University School of Medicine, currently serves as Chair of the Endocrine Fellowship Curriculum Committee, is a member of the Institutional Review Board and the Clinical Competency Committee at MGH, a subspecialty core educator for endocrinology, and the Director of the Endocrine and Neuroendocrine Electives for MGH medical residents. He has also served on several national and international Committees in professional organizations, including the Endocrine Society, the American Association of Clinical Endocrinologists and the Pituitary Society.

Disclosures:

No relevant financial relationships.
Post-test, Panel Discussion, and Q&A
John D. Carmichael, MD(Co-Panelist)
Keck School of Medicine of USC, Los Angeles, CA, USA
Dr. Carmichael is an associate professor of clinical medicine in the Department of Medicine's division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC. He is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus. Dr. Carmichael has written articles for The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes and Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee. After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.

Disclosures:

Advisory Board: Novo Nordisk, Recordati
Research Investigator: Critics, Chiasma, Novartis Strongbridge Biopharma
Nicholas A. Tritos, MD, DSc(Co-Panelist)
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Dr. Tritos is a staff neuroendocrinologist in the Neuroendocrine and Pituitary Tumor Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital (MGH) in Boston. He completed medical studies at The University of Athens (MD, DSc) and at Harvard Medical School (MMSc) where he now serves as Associate Professor of Medicine. Dr. Tritos completed his postgraduate medical training at Beth Israel Medical Center in Boston and received board certifications from the American Board of Internal Medicine in Endocrinology, Diabetes and Metabolism and Internal Medicine. Dr. Tritos’ main clinical and research interests include pituitary disease, growth hormone deficiency in adults and regulation of energy homeostasis. He mainly conducts clinical research focusing on pituitary tumors and growth hormone deficiency in adults. Dr. Tritos has served on the Curriculum Committee at Tufts University School of Medicine, currently serves as Chair of the Endocrine Fellowship Curriculum Committee, is a member of the Institutional Review Board and the Clinical Competency Committee at MGH, a subspecialty core educator for endocrinology, and the Director of the Endocrine and Neuroendocrine Electives for MGH medical residents. He has also served on several national and international Committees in professional organizations, including the Endocrine Society, the American Association of Clinical Endocrinologists and the Pituitary Society.

Disclosures:

No relevant financial relationships.
supported by:
This program is supported by an educational grant from Novo Nordisk, Inc., and Sandoz, Inc.
 

Learning Objectives:

  • Apply current guidelines, testing, and criteria in the individualized management of adult GHD
  • Recognize and effectively address barriers towards treatment adherence in pediatric patients transitioning to adult care
  • Analyze currently approved therapeutic regimens as well as emerging pharmaceuticals and delivery devices for adult patients with GHD.
Legislation & Regulations Affecting Endocrinologists: What You Need to Know About Medicare Physician Payment, Telehealth Expansion, and Drug Pricing
Not Currently Available
Joshua J. Joseph, MD, MPH, FAHA(Panelist)
The Ohio State University Wexner Medical Division of Endocrinology, Diabetes and Metabolism, Columbus, OH, USA
Dr. Joshua Joseph is the Assistant Professor, Endocrinology, Diabetes and Metabolism, at The Ohio State University Wexner Medical Center. Dr. Joseph is an alumnus of Boston University School of Medicine, during which he spent two years at the National Institutes of Health in the Medical Research Scholars Program. In his diabetes and cardiovascular disease clinic, Dr. Joseph focuses on lifestyle behaviors and medical therapeutics through a team-based, patient-centered approach to living with diabetes that is tailored to provide patients with the necessary tools to successfully manage their diabetes.

Disclosures:

Associate Editor, Ethnicity & Health, American Heart Association Science Advisory and Coordinating Committee, Buckeye Health Plan Board Member
Erika Miller, JD(Panelist)
CRD Associates, Washington, DC, USA
Erika Miller is a consultant to the Endocrine Society where she brings her broad experience in government relations representing a range non- profit organizations ranging from medical specialty societies, coalitions, and patient advocacy organizations, including a number engaged on women’s health issues. Erika has expertise in the intricacies of Medicare policy and provides guidance on health policy, health care payment and quality.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Analyze new legislation and regulations concerning Medicare payment, telehealth expansion, and drug pricing
  • Understand the impact of the Medicare physician payment rule on their practice
  • Identify opportunities to share information with their patients about telehealth expansion and access to lower cost medications
  • Influence these policies and share their concerns by joining Endocrine Society campaigns
Thyroid Eye Disease: Early Diagnosis, Referral, and Treatment With TEPEZZA® (teprotumumab-trbw)
Not Currently Available
Raymond S. Douglas, MD, PhD
Cedars-Sinai Medical Center, Los Angeles, CA, USA

Disclosures:

Consultant for Horizon Therapeutics and Immunovant.
sponsored by:
Horizon Therapeutics
 

Learning Objectives:

  • Describe the pathophysiology of Thyroid Eye Disease (TED)
  • Review the clinical signs and symptoms of TED to ensure an early diagnosis and referral to a TED specialist
  • Emphasize the importance of multidisciplinary TED management
  • Provide an overview of TEPEZZA efficacy, safety, and mechanism of action for the treatment of TED
Welcome and Introduction
Not Currently Available
Marc-Andre Cornier, MD
University of Colorado School of Medicine, Aurora, Colorado, USA
Dr. Cornier, is a Professor of Medicine and Associate Division Head at the University of Colorado in the Division of Endocrinology, Metabolism & Diabetes. He also serves as the Associate Director of the Anschutz Health & Wellness Center, Medical Director of the Lipoprotein Apheresis Program, and Director of the Lipid Disorders Clinic. Dr. Cornier is an active clinical and translational investigator, with primary research interests focused on investigating obesity, food intake, regulation, neuroimaging, and insulin action. His clinical interests include the management of complex Lipid Disorders, both Type 1 and Type 2 Diabetes Mellitus, Metabolic Syndrome and Obesity. Dr. Cornier received his medical degree from the Medical College of Georgia. He completed his medical internship and residency at Georgetown University Medical Center, and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Health Sciences Center. He is an active volunteer and maintains memberships in the Endocrine Society, American Diabetes Association, American Heart Association, and the Obesity Society. Dr. Cornier is the Chair of the Clinical Endocrinology Update (CEU) Steering Committee.

Disclosures:

No relevant financial relationships.
Master Clinician: Management of Aggressive Pituitary Tumors: When to Consider Alternative Nonsurgical Treatments
Not Currently Available
Lisa B. Nachtigall, MD(Moderator)
Massachusetts General Hospital, Boston, MA, USA
Dr. Nachtigall is an Associate Professor of Medicine at Harvard Medical School, clinical director of the Neuroendocrine and Pituitary Tumor Clinical Center, director of International Programs for the Endocrine Division at Massachusetts General Hospital, and clerkship director for Neuroendocrine at Harvard Medical School. Dr. Nachtigall earned her medical degree from New York University (NYU) School of Medicine, completed her internship and residency in internal medicine at Bellevue Hospital Center/NYU school of Medicine, and a clinical fellowship in endocrinology and metabolism at Massachusetts General Hospital/Harvard Medical School. She has been published in many high impact journals, serves on the editorial board of Pituitary and has presented at many national and international medical conferences in the field of pituitary disorders.

Disclosures:

Advisory Board Member: Recordati, Strongbridge
Research Investigator: Chiasma
Anthony P. Heaney, MD, PhD(Panelist)
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
Edward R. Laws, MD(Panelist)
Brigham and Women's Hospital, Boston, MA, USA
Dr. Laws received his bachelor's degree from Princeton University with honors in Economics and Sociology in the Special Program in American Civilization, and then attended the Johns Hopkins University School of Medicine in Baltimore, Maryland. He did his surgical internship and neurosurgical residency at Johns Hopkins. After completing his residency, he joined the faculty at the Johns Hopkins Medical School. In 1972, he moved to the Mayo Clinic in Rochester, Minnesota where he became Professor of Neurosurgery and developed major interests in Pituitary and Brain tumor treatment and research.  In 1987, he became Professor and Chairman of the Department of Neurosurgery at the George Washington University in Washington, DC, and in 1992 joined the faculty of the University of Virginia as Professor of Neurosurgery and Professor of Medicine, developing a Multidisciplinary Pituitary Center there. Subsequently, he was Professor of Neurosurgery at Stanford University. In 2008, he established the Pituitary/Neuroendocrine Center at Brigham and Women's Hospital, where he currently is Professor of Neurosurgery at Harvard Medical School. During his surgical career he has operated upon more than 8,000 brain tumors, of which over 6,000 have been pituitary lesions. Dr. Laws has served as President of the World Federation of Neurosurgical Societies, President of the Congress of Neurological Surgeons, Editor of Neurosurgery, President of the American Association of Neurological Surgeons, and President of the Pituitary Society. He has been the fifth neurosurgeon to become President of the American College of Surgeons and was elected to membership in the National Academy of Medicine. He remains actively involved in Brain and Pituitary tumor research and surgery.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain what the current concept of an "aggressive" pituitary tumor is
  • Discuss the role of a multidisciplinary approach to management of this entity
  • Identify up-to-date therapeutic options for these tumors.
Meet the Professor: Thyroid on the Internet: Myths and Misperceptions
Not Currently Available
Anne R. Cappola, MD, ScM
University of Pennsylvania, Philadelphia, PA, USA
Dr. Cappola is a Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism, Director of Clinical Research in the Department of Medicine, and Director of the CTSA-funded Center for Human Phenomic Science at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cappola directs an NIH-funded research program on the hormonal alterations that occur with aging and the clinical impact of these changes, with a focus on the clinical impact of subclinical thyroid dysfunction in older individuals. Dr. Cappola is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the Interurban Clinical Club and an Associate Editor for JAMA.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Describe the types of thyroid information that patients find on the internet
  • Review scientific evidence that supports or refutes internet claims as well as areas for which there is no scientific evidence
  • Select a framework for discussing thyroid information found on the internet with patients.
The Year in Thyroid
Not Currently Available
Anthony Hollenberg, MD
Weill Cornell Medicine, New York, NY, USA
Dr. Hollenberg is the Sanford I. Weill Chair of Medicine in the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and the Physician-in-Chief at New York-Presbyterian Hospital. Dr. Hollenberg received his M.D. from the University of Calgary in Canada in 1986. He completed his Internal Medicine residency in 1989 and was Chief Resident in Medicine from 1990 to 1991 at the Beth Israel Hospital. Dr. Hollenberg then completed a fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital in 1993 and was recruited back to Beth Israel to start his laboratory. From 2011 until his recruitment to Weill Cornell Medicine and New York-Presbyterian Hospital, Dr. Hollenberg was Chief of the Division of Endocrinology, Diabetes and Metabolism, at Beth Israel Deaconess Medical Center and Director of Clinical and Translational Research Training Programs at Harvard Catalyst and Harvard Medical School where he was also a Professor of Medicine. Dr. Hollenberg’s research focuses on the hormonal regulation of metabolism, with a particular emphasis on the role of thyroid hormone. His work has important ramifications for the regulation of body weight and metabolism. Additionally, his laboratory focuses on understanding thyroid gland development and the possibilities for regenerative medicine.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Discuss important recent advances in the field of thyroid cancer in 2021
  • Evaluate the most important new evidence related to thyroid dysfunction
  • Describe new data regarding thyroid physiology.
6,000 + Transsphenoidal Operations: Lessons Learned
Not Currently Available
Edward R. Laws, MD
Brigham and Women's Hospital, Boston, MA, USA
Dr. Laws received his bachelor's degree from Princeton University with honors in Economics and Sociology in the Special Program in American Civilization, and then attended the Johns Hopkins University School of Medicine in Baltimore, Maryland. He did his surgical internship and neurosurgical residency at Johns Hopkins. After completing his residency, he joined the faculty at the Johns Hopkins Medical School. In 1972, he moved to the Mayo Clinic in Rochester, Minnesota where he became Professor of Neurosurgery and developed major interests in Pituitary and Brain tumor treatment and research.  In 1987, he became Professor and Chairman of the Department of Neurosurgery at the George Washington University in Washington, DC, and in 1992 joined the faculty of the University of Virginia as Professor of Neurosurgery and Professor of Medicine, developing a Multidisciplinary Pituitary Center there. Subsequently, he was Professor of Neurosurgery at Stanford University. In 2008, he established the Pituitary/Neuroendocrine Center at Brigham and Women's Hospital, where he currently is Professor of Neurosurgery at Harvard Medical School. During his surgical career he has operated upon more than 8,000 brain tumors, of which over 6,000 have been pituitary lesions. Dr. Laws has served as President of the World Federation of Neurosurgical Societies, President of the Congress of Neurological Surgeons, Editor of Neurosurgery, President of the American Association of Neurological Surgeons, and President of the Pituitary Society. He has been the fifth neurosurgeon to become President of the American College of Surgeons and was elected to membership in the National Academy of Medicine. He remains actively involved in Brain and Pituitary tumor research and surgery.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain the objectives and technical aspects of surgery for pituitary tumors
  • Describe the pituitary tumor subtypes that are most likely to be aggressive
  • Discuss postoperative hyponatremia and its consequences
Meet the Professor: Management of Hyperthyroidism in Pregnancy
Not Currently Available
Susan J. Mandel, MD, MPH
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Recognize gestational changes in thyroid hormone physiology
  • Apply evidence-based recommendations for the treatment of maternal hyperthyroidism
  • Describe testing for potential fetal and neonatal thyrotoxicosis.
Thyroid Cancer Overdiagnosis
Not Currently Available
Julie Ann Sosa, MD, MA
University of California, San Francisco, San Francisco, CA, USA
Dr. Sosa is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is an NIH- and FDA-funded investigator and author of more than 340 peer-reviewed publications and 80 book chapters and reviews, all largely focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. She has authored or edited 7 books. Dr Sosa is Treasurer of the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines. She is the Editor-in-Chief of the World Journal of Surgery. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton, MA at Oxford, and MD at Johns Hopkins, where she completed the Halsted residency and a fellowship.

Disclosures:

Member, Data Monitoring Committee, Medullary Thyroid Cancer Consortium Registry: GlaxoSmithKline, Novo Nordisk, Astra Zeneca, Eli Lilly
Institutional Research Funding: Exelixis and Eli Lilly
 

Learning Objectives:

  • Describe the evolving epidemiology of thyroid cancer in the U.S
  • Summarize the different interpretations of the data
  • Evaluate the evidence supporting different explanations.
Meet the Professor: Challenges in the Management of Cushing's Disease
Not Currently Available
Anthony P. Heaney, MD, PhD
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
 

Learning Objectives:

  • Describe the spectrum of Cushing’s disease and its variable presentation
  • Outline the expanding therapeutic options in Cushing’s disease
  • Discuss the remaining unmet medical need and future goals.
Meet the Professor: Current Trends in Treatment of Hypopituitarism
Not Currently Available
Lisa B. Nachtigall, MD
Massachusetts General Hospital, Boston, MA, USA
Dr. Nachtigall is an Associate Professor of Medicine at Harvard Medical School, clinical director of the Neuroendocrine and Pituitary Tumor Clinical Center, director of International Programs for the Endocrine Division at Massachusetts General Hospital, and clerkship director for Neuroendocrine at Harvard Medical School. Dr. Nachtigall earned her medical degree from New York University (NYU) School of Medicine, completed her internship and residency in internal medicine at Bellevue Hospital Center/NYU school of Medicine, and a clinical fellowship in endocrinology and metabolism at Massachusetts General Hospital/Harvard Medical School. She has been published in many high impact journals, serves on the editorial board of Pituitary and has presented at many national and international medical conferences in the field of pituitary disorders.

Disclosures:

Advisory Board Member: Recordati, Strongbridge
Research Investigator: Chiasma
 

Learning Objectives:

  • Recognize the clinical presentation of hypopituitarism
  • List the biochemical tests used to diagnose hypopituitarism
  • Explain the current management of hypopituitarism.
Thyroid Tumor Board
Not Currently Available
Anne R. Cappola, MD, ScM(Moderator)
University of Pennsylvania, Philadelphia, PA, USA
Dr. Cappola is a Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism, Director of Clinical Research in the Department of Medicine, and Director of the CTSA-funded Center for Human Phenomic Science at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cappola directs an NIH-funded research program on the hormonal alterations that occur with aging and the clinical impact of these changes, with a focus on the clinical impact of subclinical thyroid dysfunction in older individuals. Dr. Cappola is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the Interurban Clinical Club and an Associate Editor for JAMA.

Disclosures:

No relevant financial relationships.
Susan J. Mandel, MD, MPH(Panelist)
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
Julie Ann Sosa, MD, MA, FACS(Panelist)
University of California, San Francisco, San Francisco, CA, USA
Dr. Sosa is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is an NIH- and FDA-funded investigator and author of more than 340 peer-reviewed publications and 80 book chapters and reviews, all largely focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. She has authored or edited 7 books. Dr Sosa is Treasurer of the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines. She is the Editor-in-Chief of the World Journal of Surgery. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton, MA at Oxford, and MD at Johns Hopkins, where she completed the Halsted residency and a fellowship.

Disclosures:

Member, Data Monitoring Committee, Medullary Thyroid Cancer Consortium Registry: GlaxoSmithKline, Novo Nordisk, Astra Zeneca, Eli Lilly
Institutional Research Funding: Exelixis and Eli Lilly
 

Learning Objectives:

  • Apply practice guideline recommendations to the management of differentiated thyroid cancer
  • Discuss the evidence that serves as the underpinning to those guidelines
  • Explain the controversies that might exist around management options.
Meet the Professor: The Thyroid and Body Weight
Not Currently Available
Anthony Hollenberg, MD
Weill Cornell Medicine, New York, NY, USA
Dr. Hollenberg is the Sanford I. Weill Chair of Medicine in the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and the Physician-in-Chief at New York-Presbyterian Hospital. Dr. Hollenberg received his M.D. from the University of Calgary in Canada in 1986. He completed his Internal Medicine residency in 1989 and was Chief Resident in Medicine from 1990 to 1991 at the Beth Israel Hospital. Dr. Hollenberg then completed a fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital in 1993 and was recruited back to Beth Israel to start his laboratory. From 2011 until his recruitment to Weill Cornell Medicine and New York-Presbyterian Hospital, Dr. Hollenberg was Chief of the Division of Endocrinology, Diabetes and Metabolism, at Beth Israel Deaconess Medical Center and Director of Clinical and Translational Research Training Programs at Harvard Catalyst and Harvard Medical School where he was also a Professor of Medicine. Dr. Hollenberg’s research focuses on the hormonal regulation of metabolism, with a particular emphasis on the role of thyroid hormone. His work has important ramifications for the regulation of body weight and metabolism. Additionally, his laboratory focuses on understanding thyroid gland development and the possibilities for regenerative medicine.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Explain how thyroid hormone influences human physiology
  • Describe the metabolic effects of thyroid hormone
  • Identify novel mechanisms by which thyroid hormones may regulate body weight and metabolic disease.
Update on the Management of Thyroid Nodules
Not Currently Available
Susan J. Mandel, MD, MPH
University of Pennsylvania, Philadelphia, PA, USA
Dr. Mandel is Professor of Medicine and Radiology and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing group for the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2022 ATA Guidelines for Patients with Thyroid nodules. Dr. Mandel initiated the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society's Distinguished Educator Award and the 2019 ATA WIT Woman of the Year award. She is past President of the Endocrine Society. Dr. Mandel has over 90 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. .She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Disclosures:

No relevant financial relationships.
 

Learning Objectives:

  • Apply evidence-based evaluation for patients with thyroid nodules
  • Discuss the association of sonographic imaging with cancer risk and its application to FNA decision making
  • Assess the Bethesda cytology classification for reporting thyroid nodule FNA results and the indications for molecular testing.
Year in Clinical Pituitary
Not Currently Available
Anthony P. Heaney, MD, PhD
University of California, Los Angeles, Los Angeles, CA, USA
Dr. Heaney is a Professor of Medicine at UCLA where he holds the Burnett Family Endowed Chair in Neuroendocrinology. He graduated in Medicine from Queen’s University of Belfast, Northern Irelandand following internship and medical residency, he was honorary lecturer at the University of Manchester and is a Fellow of The Royal College of Physicians. As a Fulbright Scholar, he pursued translational research at CSMC, Los Angeles and then moved to UCLA in 2005. His research focuses on the pathogenesis of pituitary tumors and identification of novel molecular therapeutic targets in pituitary tumors and other NETs. He has authored multiple peer-reviewed publications, is a former President of the Pituitary Society, a prior Associate Editor for JCEM and has served on committees for the Endocrine and Pituitary Societies, and the European Society of Endocrinology.

Disclosures:

Advisory Board Member: Strongbridge
 

Learning Objectives:

  • Discuss the highlights in translational and clinical pituitary research in the prior year
  • Summarize and provide a critical appraisal of high impact studies in the Neuroendocrine/Pituitary field published in 2020-2021
  • Describe the practical clinical application of the published findings.

Attempting to automatically open Zoom webinar. If zoom does not open, please use this link to:

Open Zoom